[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_3dbc0abc-7424-474c-b778-ee6c6d187193":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:3dbc0abc-7424-474c-b778-ee6c6d187193,\"}":84},{"code":4,"data":5,"meta":24},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":26,"manageAffiliations":33,"indexDatabases":48,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},"3dbc0abc-7424-474c-b778-ee6c6d187193","2023-05-29T10:26:18.183+00:00","2025-11-21T09:58:12.526+00:00",[],"Current-Oncology",{"country":12,"eissn":14,"issn":16,"title":18,"introduce":20},{"VOID":13},"CA",{"VOID":15},"11980052",{"VOID":17},"17187729",{"EN":19},"Current Oncology",{"EN":21},"Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.","PUBLISHER","PENDING",null,0,[27],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":29,"label":30,"description":32,"parentId":24,"standard":24,"scholarHubFieldId":24},"d9687dc3-fd83-46ff-aef4-1925044c24eb",[],{"EN":31},"Oncology",{},[34,41],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":36,"slug":24,"properties":37,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":40,"statistic":24},"60287fcb-0b07-4c46-bd13-5f5a3930fd28",[],{"title":38},{"EN":39},"MDPI",[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":43,"slug":24,"properties":44,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":47,"statistic":24},"629d0dc5-fc8d-4271-971f-1cc99a7b1cb2",[],{"title":45},{"EN":46},"Multidisciplinary Digital Publishing Institute (MDPI)",[],[49,66],{"id":50,"indexDatabase":51,"url":61,"indexYears":62,"academicFieldIds":63,"indexDatabaseRanking":65},"08496abc-59dd-4179-9ac7-a9ab9aea7bb0",{"id":52,"createTime":24,"updateTime":24,"relativeEntities":53,"label":54,"description":56,"key":58,"publicationTags":59,"standard":24},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":55,"VI":55},"Scopus - Elsevier",{"EN":55,"VI":57},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[60],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F29319","1998-2025",[64],"462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","SCOPUS__Q3",{"id":67,"indexDatabase":68,"url":80,"indexYears":24,"academicFieldIds":81,"indexDatabaseRanking":24},"63ddb846-9fde-43a8-bf12-eb602debad30",{"id":69,"createTime":24,"updateTime":24,"relativeEntities":70,"label":71,"description":73,"key":76,"publicationTags":77,"standard":24},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":72,"VI":72},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":74,"VI":75},"SCIE database","Cơ sở dữ liệu SCIE","scie",[78,79],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1198-0052",[82],"248e54de-c562-4c06-8a10-d7f8a37c06fe","https:\u002F\u002Fwww.current-oncology.com\u002Findex.php\u002Foncology",{"meta":85,"data":87},{"total":86},"22",[88,245,367,536,824,975,1154,1261,1427,1557],{"id":89,"createTime":90,"updateTime":91,"relativeEntities":92,"slug":93,"properties":94,"entityType":101,"verifyStatus":102,"verifyTime":103,"verifyNote":104,"languages":105,"translateLanguages":24,"viewCount":25,"primaryUrl":107,"fullTextUrl":108,"authors":109,"publicationType":189,"publisherRelationship":190,"citationCount":236,"citationInfo":237,"publishDate":240,"publishYear":238,"citationAnalyzeStatus":241,"lastCitationAnalyze":91,"indexDatabases":242,"openAccess":24,"references":243,"isForceReanalyzing":244},"5147f3c2-c1ea-4093-be03-5e6cf3b5ecc8","2024-12-25T13:36:52.843+00:00","2026-07-12T11:56:27.785+00:00",[],"Evaluation-of-a-routine-screening-program-with-tuberculin-skin-testing-on-rates-of-detection-of-latent-tuberculosis-infection-and-prevention-of-active-tuberculosis-in-patients-with-multiple-myeloma-at-a-Canadian-cancer-centre",{"title":95,"gsPaper":97,"doi":99},{"EN":96},"Evaluation of a routine screening program with tuberculin skin testing on rates of detection of latent tuberculosis infection and prevention of active tuberculosis in patients with multiple myeloma at a Canadian cancer centre",{"VOID":98},"[\"477119898611056719\"]",{"VOID":100},"10.3747\u002Fco.27.5577","PUBLICATION","VERIFIED","2024-12-25T13:36:52.842+00:00","Auto Verify",[106],"EN","https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC7339840\u002F","https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC7339840\u002Fpdf\u002Fconc-27-e246.pdf",[110,127,143,161,175],{"id":111,"sortIndex":25,"researcher":24,"roles":112,"affiliations":113,"properties":122,"displayName":124,"givenName":24,"familyName":24},"2cb6c3a8-123a-4801-89e9-1497dc3cfdf7",[],[114],{"id":115,"sortIndex":25,"affiliation":116,"properties":24},"e411e38b-6369-4086-b991-24a7ba2f3e85",{"id":115,"createTime":24,"updateTime":24,"relativeEntities":117,"slug":24,"properties":118,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":121,"statistic":24},[],{"title":119},{"EN":120},"Department of General Internal Medicine, University Health Network, University of Toronto, Toronto, ON",[],{"title":123,"gsAuthor":125},{"EN":124},"M Gitman",{"VOID":126},"ei7n3tkAAAAJ",{"id":128,"sortIndex":129,"researcher":24,"roles":130,"affiliations":131,"properties":140,"displayName":142,"givenName":24,"familyName":24},"092eda05-c053-49d4-9607-ceffa15f2146",1,[],[132],{"id":133,"sortIndex":25,"affiliation":134,"properties":24},"03396e10-e98b-40e5-bd1b-a67dbf0155c6",{"id":133,"createTime":24,"updateTime":24,"relativeEntities":135,"slug":24,"properties":136,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":139,"statistic":24},[],{"title":137},{"EN":138},"Immunocompromised Hosts Infectious Diseases Service, Division of Infectious Diseases, Department of Medicine, University Health Network, University of Toronto, Toronto, ON",[],{"title":141},{"EN":142},"J Vu",{"id":144,"sortIndex":145,"researcher":24,"roles":146,"affiliations":147,"properties":156,"displayName":158,"givenName":24,"familyName":24},"3aa9f6c4-7236-43cd-9231-0c60422368d2",2,[],[148],{"id":149,"sortIndex":25,"affiliation":150,"properties":24},"20b67e9d-08a2-40d3-b335-2054b3fee549",{"id":149,"createTime":24,"updateTime":24,"relativeEntities":151,"slug":24,"properties":152,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":155,"statistic":24},[],{"title":153},{"EN":154},"Division of Medical Oncology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON",[],{"title":157,"gsAuthor":159},{"EN":158},"T Nguyen",{"VOID":160},"y_SSBIYAAAAJ",{"id":162,"sortIndex":163,"researcher":24,"roles":164,"affiliations":165,"properties":172,"displayName":174,"givenName":24,"familyName":24},"bce8d873-0554-4f5e-8578-b48d816d078a",3,[],[166],{"id":149,"sortIndex":25,"affiliation":167,"properties":24},{"id":149,"createTime":24,"updateTime":24,"relativeEntities":168,"slug":24,"properties":169,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":171,"statistic":24},[],{"title":170},{"EN":154},[],{"title":173},{"EN":174},"C Chen",{"id":176,"sortIndex":177,"researcher":24,"roles":178,"affiliations":179,"properties":186,"displayName":188,"givenName":24,"familyName":24},"be6394a4-0a12-41c1-a4a8-0034ec42a95e",4,[],[180],{"id":133,"sortIndex":25,"affiliation":181,"properties":24},{"id":133,"createTime":24,"updateTime":24,"relativeEntities":182,"slug":24,"properties":183,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":185,"statistic":24},[],{"title":184},{"EN":138},[],{"title":187},{"EN":188},"C Rotstein","ARTICLE",{"url":24,"publisher":191,"properties":229},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":192,"slug":10,"properties":193,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":198,"manageAffiliations":203,"indexDatabases":214,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":194,"eissn":195,"issn":196,"title":197},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[199],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":200,"label":201,"description":202,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[204,209],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":205,"slug":24,"properties":206,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":208,"statistic":24},[],{"title":207},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":210,"slug":24,"properties":211,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":213,"statistic":24},[],{"title":212},{"EN":46},[],[215,222],{"id":50,"indexDatabase":216,"url":61,"indexYears":62,"academicFieldIds":221,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":217,"label":218,"description":219,"key":58,"publicationTags":220,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":223,"url":80,"indexYears":24,"academicFieldIds":228,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":224,"label":225,"description":226,"key":76,"publicationTags":227,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":230,"pages":232,"volume":234},{"VOID":231},"3",{"VOID":233},"e246",{"VOID":235},"27",10,{"total":236,"publishYear":238,"statisticByYear":239},2020,{},"2020-06-01","DONE_ANALYZE_CITATION",[65,78],[],false,{"id":246,"createTime":247,"updateTime":247,"relativeEntities":248,"slug":249,"properties":250,"entityType":101,"verifyStatus":102,"verifyTime":247,"verifyNote":104,"languages":265,"translateLanguages":24,"viewCount":25,"primaryUrl":266,"fullTextUrl":24,"authors":267,"publicationType":189,"publisherRelationship":316,"citationCount":362,"citationInfo":363,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":365,"openAccess":24,"references":366,"isForceReanalyzing":244},"72443004-5b92-438c-b20e-410eedf1ca3f","2025-01-06T00:08:26.696+00:00",[],"Advances-in-the-Management-of-Metastatic-Breast-Cancer-Options-Beyond-First-Line-Chemotherapy",{"mag":251,"pmc":253,"openalex":255,"abstract":257,"title":259,"pm":261,"doi":263},{"VOID":252},"1977704967",{"VOID":254},"3320230",{"VOID":256},"W1977704967",{"EN":258},"\u003Cjats:p>This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (mbc). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality. Eribulin mesylate is the first monotherapy to significantly increase overall survival in patients with pretreated mbc, but nab-paclitaxel offers a novel and safer mode of delivery in comparison with standard taxanes. By contrast, the use of ixabepilone will be limited for now, until the associated neurotoxicity can be better managed. Alongside a brief overview of the other major chemotherapies currently in use, we have aimed to provide a Canadian context for how these novel agents may be integrated into clinical practice.\u003C\u002Fjats:p>",{"EN":260},"Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy",{"VOID":262},"22514495",{"VOID":264},"10.3747\u002Fco.19.1024",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F19\u002F2\u002F1024",[268,285,302],{"id":269,"sortIndex":25,"researcher":24,"roles":270,"affiliations":271,"properties":280,"displayName":282,"givenName":24,"familyName":24},"950fc990-4589-4441-81e4-7422beb4d17f",[],[272],{"id":273,"sortIndex":25,"affiliation":274,"properties":24},"25a634b5-abec-495f-b46c-573f501849db",{"id":273,"createTime":24,"updateTime":24,"relativeEntities":275,"slug":24,"properties":276,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":279,"statistic":24},[],{"title":277},{"EN":278},"Hematology-Oncology Service, Centre Hospitalier de l'Université de Montréal, Montreal, QC.",[],{"title":281,"openalex":283},{"EN":282},"J-P. Ayoub",{"VOID":284},"A5110473915",{"id":286,"sortIndex":129,"researcher":24,"roles":287,"affiliations":288,"properties":297,"displayName":299,"givenName":24,"familyName":24},"e40413e9-bd92-4fa5-a9ba-76aa8647df7f",[],[289],{"id":290,"sortIndex":25,"affiliation":291,"properties":24},"e5460568-6b62-436c-872c-ecd41bd5a130",{"id":290,"createTime":24,"updateTime":24,"relativeEntities":292,"slug":24,"properties":293,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":296,"statistic":24},[],{"title":294},{"EN":295},"The Ottawa hospital Cancer Centre",[],{"title":298,"openalex":300},{"EN":299},"S. Verma",{"VOID":301},"A5113604214",{"id":303,"sortIndex":145,"researcher":24,"roles":304,"affiliations":305,"properties":312,"displayName":299,"givenName":24,"familyName":24},"1d0c7a44-23e8-4f91-b0e0-7c3cf882f52d",[],[306],{"id":290,"sortIndex":25,"affiliation":307,"properties":24},{"id":290,"createTime":24,"updateTime":24,"relativeEntities":308,"slug":24,"properties":309,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":311,"statistic":24},[],{"title":310},{"EN":295},[],{"title":313,"openalex":314},{"EN":299},{"VOID":315},"A5048708787",{"url":24,"publisher":317,"properties":355},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":318,"slug":10,"properties":319,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":324,"manageAffiliations":329,"indexDatabases":340,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":320,"eissn":321,"issn":322,"title":323},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[325],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":326,"label":327,"description":328,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[330,335],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":331,"slug":24,"properties":332,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":334,"statistic":24},[],{"title":333},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":336,"slug":24,"properties":337,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":339,"statistic":24},[],{"title":338},{"EN":46},[],[341,348],{"id":50,"indexDatabase":342,"url":61,"indexYears":62,"academicFieldIds":347,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":343,"label":344,"description":345,"key":58,"publicationTags":346,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":349,"url":80,"indexYears":24,"academicFieldIds":354,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":350,"label":351,"description":352,"key":76,"publicationTags":353,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":356,"pages":358,"volume":360},{"VOID":357},"2",{"VOID":359},"91-105",{"VOID":361},"19",16,{"total":362,"publishYear":24,"statisticByYear":364},{"2013":177,"2014":129,"2015":129,"2016":129,"2017":129,"2018":129,"2019":145,"2020":145,"2021":145,"2022":129},[],[],{"id":368,"createTime":369,"updateTime":369,"relativeEntities":370,"slug":371,"properties":372,"entityType":101,"verifyStatus":102,"verifyTime":369,"verifyNote":104,"languages":387,"translateLanguages":24,"viewCount":25,"primaryUrl":388,"fullTextUrl":24,"authors":389,"publicationType":189,"publisherRelationship":486,"citationCount":531,"citationInfo":532,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":534,"openAccess":24,"references":535,"isForceReanalyzing":244},"f688d784-56bf-4657-8e55-e0b9d8c2f514","2024-12-26T17:11:42.439+00:00",[],"Area-Level-Income-Disparities-in-Colorectal-Screening-in-Canada-Evidence-to-Inform-Future-Surveillance",{"mag":373,"pmc":375,"openalex":377,"abstract":379,"title":381,"pm":383,"doi":385},{"VOID":374},"2943498246",{"VOID":376},"6476461",{"VOID":378},"W2943498246",{"EN":380},"\u003Cjats:p>Background: Participation in colorectal screening remains low even in countries with universal health coverage. Area-level determinants of low screening participation in Canada remain poorly understood. Methods: We assessed the association between area-level income and two indicators of colorectal screening (having never been screened, having not been screened recently) by linking census-derived local area-level income data with self-reported screening data from urban-dwelling respondents to the Canadian Community Health Survey (50–75 years of age, cycles 2005 and 2007, n = 18,362) who reported no known risk factors for colorectal cancer. Generalized estimating equation Poisson models estimated the prevalence ratios and differences for having never been screened and having not been screened recently, adjusting for individual-level income, education, marital status, having a regular physician, age, and sex. Results: About 53% of the study population had never been screened. Among individuals who had ever been screened, 35% had been screened recently. Adjusting for covariates, lower area-level income was associated with having never been screened [covariate-adjusted prevalence ratios: 1.24 for quartile 1; 95% confidence limits (cl): 1.16, 1.34; 1.25 for quartile 2; 95% cl: 1.15, 1.33; 1.15 for quartile 3; 95% cl: 1.08, 1.23]. Among individuals who had been screened in their lifetime, area-level income was not associated with having not been screened recently. Conclusions: Lower area-level income is associated with having never been screened for colorectal cancer even after adjusting for individual socioeconomic factors. Those findings highlight the potential importance of socioeconomic contexts for colorectal screening initiation and merit attention in both future research and surveillance efforts.\u003C\u002Fjats:p>",{"EN":382},"Area-Level Income Disparities in Colorectal Screening in Canada: Evidence to Inform Future Surveillance",{"VOID":384},"31043818",{"VOID":386},"10.3747\u002Fco.26.4279",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F26\u002F2\u002F4279",[390,417,440,463],{"id":391,"sortIndex":25,"researcher":24,"roles":392,"affiliations":393,"properties":410,"displayName":414,"givenName":24,"familyName":24},"f37466e1-6657-4d88-b16e-41a1b064d867",[],[394,402],{"id":395,"sortIndex":25,"affiliation":396,"properties":24},"f5f29a47-15fb-47f1-9185-8a83a11df69b",{"id":395,"createTime":24,"updateTime":24,"relativeEntities":397,"slug":24,"properties":398,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":401,"statistic":24},[],{"title":399},{"EN":400},"Centre de recherche du Centre Hospitalier de l'Université de Montréal, 850 rue Saint-Denis, Tour St-Antoine, S03-456, Montreal, QC H2X A09, Canada",[],{"id":403,"sortIndex":129,"affiliation":404,"properties":24},"7efd343f-20ef-4dc2-bcc5-605e981b2fda",{"id":403,"createTime":24,"updateTime":24,"relativeEntities":405,"slug":24,"properties":406,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":409,"statistic":24},[],{"title":407},{"EN":408},"Department of Social and Preventive Medicine, École de Santé Publique de l'Université de Montréal Montreal, QC, Canada",[],{"orcid":411,"title":413,"openalex":415},{"VOID":412},"https:\u002F\u002Forcid.org\u002F0000-0002-8555-0399",{"EN":414},"Alexandra Blair",{"VOID":416},"A5083368089",{"id":418,"sortIndex":129,"researcher":24,"roles":419,"affiliations":420,"properties":433,"displayName":437,"givenName":24,"familyName":24},"5a7fb536-2eeb-49f6-b710-0f71909c530e",[],[421,427],{"id":395,"sortIndex":25,"affiliation":422,"properties":24},{"id":395,"createTime":24,"updateTime":24,"relativeEntities":423,"slug":24,"properties":424,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":426,"statistic":24},[],{"title":425},{"EN":400},[],{"id":403,"sortIndex":129,"affiliation":428,"properties":24},{"id":403,"createTime":24,"updateTime":24,"relativeEntities":429,"slug":24,"properties":430,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":432,"statistic":24},[],{"title":431},{"EN":408},[],{"orcid":434,"title":436,"openalex":438},{"VOID":435},"https:\u002F\u002Forcid.org\u002F0000-0002-1562-1307",{"EN":437},"Lise Gauvin",{"VOID":439},"A5090908513",{"id":441,"sortIndex":145,"researcher":24,"roles":442,"affiliations":443,"properties":456,"displayName":460,"givenName":24,"familyName":24},"c2d85c6c-ec8a-462c-b129-783345d84d2f",[],[444,450],{"id":395,"sortIndex":25,"affiliation":445,"properties":24},{"id":395,"createTime":24,"updateTime":24,"relativeEntities":446,"slug":24,"properties":447,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":449,"statistic":24},[],{"title":448},{"EN":400},[],{"id":403,"sortIndex":129,"affiliation":451,"properties":24},{"id":403,"createTime":24,"updateTime":24,"relativeEntities":452,"slug":24,"properties":453,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":455,"statistic":24},[],{"title":454},{"EN":408},[],{"orcid":457,"title":459,"openalex":461},{"VOID":458},"https:\u002F\u002Forcid.org\u002F0000-0001-8224-5543",{"EN":460},"Samiratou Ouédraogo",{"VOID":462},"A5086943897",{"id":464,"sortIndex":163,"researcher":24,"roles":465,"affiliations":466,"properties":479,"displayName":483,"givenName":24,"familyName":24},"711d205e-9db9-4191-bf78-e6f705db777c",[],[467,473],{"id":395,"sortIndex":25,"affiliation":468,"properties":24},{"id":395,"createTime":24,"updateTime":24,"relativeEntities":469,"slug":24,"properties":470,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":472,"statistic":24},[],{"title":471},{"EN":400},[],{"id":403,"sortIndex":129,"affiliation":474,"properties":24},{"id":403,"createTime":24,"updateTime":24,"relativeEntities":475,"slug":24,"properties":476,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":478,"statistic":24},[],{"title":477},{"EN":408},[],{"orcid":480,"title":482,"openalex":484},{"VOID":481},"https:\u002F\u002Forcid.org\u002F0000-0001-5364-0464",{"EN":483},"Geetanjali D. Datta",{"VOID":485},"A5040117363",{"url":24,"publisher":487,"properties":525},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":488,"slug":10,"properties":489,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":494,"manageAffiliations":499,"indexDatabases":510,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":490,"eissn":491,"issn":492,"title":493},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[495],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":496,"label":497,"description":498,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[500,505],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":501,"slug":24,"properties":502,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":504,"statistic":24},[],{"title":503},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":506,"slug":24,"properties":507,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":509,"statistic":24},[],{"title":508},{"EN":46},[],[511,518],{"id":50,"indexDatabase":512,"url":61,"indexYears":62,"academicFieldIds":517,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":513,"label":514,"description":515,"key":58,"publicationTags":516,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":519,"url":80,"indexYears":24,"academicFieldIds":524,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":520,"label":521,"description":522,"key":76,"publicationTags":523,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":526,"pages":527,"volume":529},{"VOID":357},{"VOID":528},"128-137",{"VOID":530},"26",14,{"total":531,"publishYear":24,"statisticByYear":533},{"2019":163,"2020":129,"2021":163,"2022":145,"2023":129,"2024":177},[],[],{"id":537,"createTime":538,"updateTime":538,"relativeEntities":539,"slug":540,"properties":541,"entityType":101,"verifyStatus":102,"verifyTime":538,"verifyNote":104,"languages":556,"translateLanguages":24,"viewCount":25,"primaryUrl":557,"fullTextUrl":24,"authors":558,"publicationType":189,"publisherRelationship":775,"citationCount":722,"citationInfo":820,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":822,"openAccess":24,"references":823,"isForceReanalyzing":244},"3114a1a7-c28f-4663-9013-c1edf4643988","2024-12-26T17:11:37.927+00:00",[],"Recent-Trends-in-Breast-Cervical-and-Colorectal-Cancer-Screening-Test-Utilization-in-Canada-Using-Self-Reported-Data-from-2008-and-2012",{"mag":542,"pmc":544,"openalex":546,"abstract":548,"title":550,"pm":552,"doi":554},{"VOID":543},"1600161921",{"VOID":545},"4530815",{"VOID":547},"W1600161921",{"EN":549},"\u003Cjats:p>In Canada, self-reported data from the Canadian Community Health Survey 2008 and 2012 provide an opportunity to examine overall utilization of breast, cervical, and colorectal cancer screening tests for both programmatic and opportunistic screening. Among women 50–74 years of age, utilization of screening mammography was stable (62.0% in 2008 and 63.0% in 2012). Pap test utilization for women 25–69 years of age remained high and stable across Canada in 2008 and 2012 (78.9% in 2012). The percentage of individuals 50–74 years of age who reporting having at least 1 fecal test within the preceding 2 years increased in 2012 (to 23.0% from 16.9% in 2008), but remains low. Stable rates of screening mammography utilization (about 30%) were reported in 2008 and 2012 among women 40–49 years of age, a group for which population-based screening is not recommended. Although declining over time, cervical cancer screening rates were high for women less than 25 years of age (for whom screening is not recommended). Interestingly, an increased percentage of women 70–74 years of age reported having a Pap test. In 2012, a smaller percentage of women 50–69 years of age reported having no screening test (5.9% vs. 8.5% in 2008), and more women reported having the three types of cancer screening tests (19.0% vs. 13.2%). Efforts to encourage use of screening within the recommended average-risk age groups are needed, and education for stakeholders about the possible harms of screening outside those age groups has to continue.\u003C\u002Fjats:p>",{"EN":551},"Recent Trends in Breast, Cervical, and Colorectal Cancer Screening Test Utilization in Canada, Using Self-Reported Data from 2008 and 2012",{"VOID":553},"26300668",{"VOID":555},"10.3747\u002Fco.22.2690",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F22\u002F4\u002F2690",[559,584,603,626,645,664,684,700,720,738,758],{"id":560,"sortIndex":25,"researcher":24,"roles":561,"affiliations":562,"properties":579,"displayName":581,"givenName":24,"familyName":24},"31e7a2e4-0c00-4605-b54e-68f102824108",[],[563,571],{"id":564,"sortIndex":25,"affiliation":565,"properties":24},"935e8211-a00f-4b9e-97b2-ee0c9ea64929",{"id":564,"createTime":24,"updateTime":24,"relativeEntities":566,"slug":24,"properties":567,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":570,"statistic":24},[],{"title":568},{"VI":569},"Canadian Partnership against Cancer, Toronto, ON, Canada",[],{"id":572,"sortIndex":129,"affiliation":573,"properties":24},"f4c8bb04-69e3-432d-bec5-0c6db017bf06",{"id":572,"createTime":24,"updateTime":24,"relativeEntities":574,"slug":24,"properties":575,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":578,"statistic":24},[],{"title":576},{"EN":577},"Département médecine sociale et préventive, Université Laval, Quebec, QC, Canada",[],{"title":580,"openalex":582},{"EN":581},"Diane Major",{"VOID":583},"A5108702525",{"id":585,"sortIndex":129,"researcher":24,"roles":586,"affiliations":587,"properties":596,"displayName":600,"givenName":24,"familyName":24},"141222f7-7f47-4a8b-8d7f-72856cedc1f0",[],[588],{"id":589,"sortIndex":25,"affiliation":590,"properties":24},"09ded50f-18ad-426e-879a-39372a523160",{"id":589,"createTime":24,"updateTime":24,"relativeEntities":591,"slug":24,"properties":592,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":595,"statistic":24},[],{"title":593},{"EN":594},"Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON, Canada",[],{"orcid":597,"title":599,"openalex":601},{"VOID":598},"https:\u002F\u002Forcid.org\u002F0000-0003-2487-1479",{"EN":600},"David Armstrong",{"VOID":602},"A5014881341",{"id":604,"sortIndex":145,"researcher":24,"roles":605,"affiliations":606,"properties":621,"displayName":623,"givenName":24,"familyName":24},"47e7550d-fe69-41c9-8991-93df7719f9cc",[],[607,613],{"id":564,"sortIndex":25,"affiliation":608,"properties":24},{"id":564,"createTime":24,"updateTime":24,"relativeEntities":609,"slug":24,"properties":610,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":612,"statistic":24},[],{"title":611},{"VI":569},[],{"id":614,"sortIndex":129,"affiliation":615,"properties":24},"dc23b935-0643-4871-9111-7e47e95d32a7",{"id":614,"createTime":24,"updateTime":24,"relativeEntities":616,"slug":24,"properties":617,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":620,"statistic":24},[],{"title":618},{"EN":619},"Departments of Community Health Sciences and Oncology, University of Calgary, Calgary, AB, Canada",[],{"title":622,"openalex":624},{"EN":623},"Heather Bryant",{"VOID":625},"A5113370306",{"id":627,"sortIndex":163,"researcher":24,"roles":628,"affiliations":629,"properties":638,"displayName":642,"givenName":24,"familyName":24},"9cbcb9a1-d67c-4b3e-b560-07f310b8bba4",[],[630],{"id":631,"sortIndex":25,"affiliation":632,"properties":24},"3777f8f2-7de0-4ac2-a7ed-89753cd6d955",{"id":631,"createTime":24,"updateTime":24,"relativeEntities":633,"slug":24,"properties":634,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":637,"statistic":24},[],{"title":635},{"EN":636},"Division of Medical Oncology, BC Cancer Agency, and Department of Medicine, University of British Columbia, Vancouver, BC, Canada",[],{"orcid":639,"title":641,"openalex":643},{"VOID":640},"https:\u002F\u002Forcid.org\u002F0000-0002-3679-4290",{"EN":642},"Winson Y. Cheung",{"VOID":644},"A5039850848",{"id":646,"sortIndex":177,"researcher":24,"roles":647,"affiliations":648,"properties":657,"displayName":661,"givenName":24,"familyName":24},"4a4bf2f2-d002-435f-a1ed-9e1fde8fd7aa",[],[649],{"id":650,"sortIndex":25,"affiliation":651,"properties":24},"2fc0ed09-6aa6-4af4-8e8b-d3762d331606",{"id":650,"createTime":24,"updateTime":24,"relativeEntities":652,"slug":24,"properties":653,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":656,"statistic":24},[],{"title":654},{"VI":655},"Cancercare Manitoba and University of Manitoba, Winnipeg, MB, Canada",[],{"orcid":658,"title":660,"openalex":662},{"VOID":659},"https:\u002F\u002Forcid.org\u002F0000-0002-0044-7545",{"EN":661},"Kathleen Decker",{"VOID":663},"A5086505111",{"id":665,"sortIndex":666,"researcher":24,"roles":667,"affiliations":668,"properties":677,"displayName":681,"givenName":24,"familyName":24},"135a0bdc-95e0-483a-ab68-bccd9cf0531c",5,[],[669],{"id":670,"sortIndex":25,"affiliation":671,"properties":24},"ad238287-0dcf-48ee-a2dd-8491dea156a5",{"id":670,"createTime":24,"updateTime":24,"relativeEntities":672,"slug":24,"properties":673,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":676,"statistic":24},[],{"title":674},{"EN":675},"Breast Screening Program for Newfoundland and Labrador, St. John's, NL, Canada",[],{"orcid":678,"title":680,"openalex":682},{"VOID":679},"https:\u002F\u002Forcid.org\u002F0000-0002-1321-8178",{"EN":681},"Gregory Doyle",{"VOID":683},"A5081833652",{"id":685,"sortIndex":686,"researcher":24,"roles":687,"affiliations":688,"properties":695,"displayName":697,"givenName":24,"familyName":24},"2c780aa2-c92d-41d6-a6dd-46ea3c7495f3",6,[],[689],{"id":564,"sortIndex":25,"affiliation":690,"properties":24},{"id":564,"createTime":24,"updateTime":24,"relativeEntities":691,"slug":24,"properties":692,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":694,"statistic":24},[],{"title":693},{"VI":569},[],{"title":696,"openalex":698},{"EN":697},"V. Mai",{"VOID":699},"A5111691576",{"id":701,"sortIndex":702,"researcher":24,"roles":703,"affiliations":704,"properties":713,"displayName":717,"givenName":24,"familyName":24},"0af62726-d485-48d6-a662-164e67c1bd33",7,[],[705],{"id":706,"sortIndex":25,"affiliation":707,"properties":24},"8c02f9eb-0da4-4eb1-8bf0-6f92abc9ce00",{"id":706,"createTime":24,"updateTime":24,"relativeEntities":708,"slug":24,"properties":709,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":712,"statistic":24},[],{"title":710},{"VI":711},"Department of Pathology and Laboratory Medicine Western University, London, ON, Canada",[],{"orcid":714,"title":716,"openalex":718},{"VOID":715},"https:\u002F\u002Forcid.org\u002F0000-0002-3518-7376",{"EN":717},"C. Meg McLachlin",{"VOID":719},"A5013048325",{"id":721,"sortIndex":722,"researcher":24,"roles":723,"affiliations":724,"properties":731,"displayName":735,"givenName":24,"familyName":24},"741cc6a1-f17c-4dee-8efd-405369c537f9",8,[],[725],{"id":564,"sortIndex":25,"affiliation":726,"properties":24},{"id":564,"createTime":24,"updateTime":24,"relativeEntities":727,"slug":24,"properties":728,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":730,"statistic":24},[],{"title":729},{"VI":569},[],{"orcid":732,"title":734,"openalex":736},{"VOID":733},"https:\u002F\u002Forcid.org\u002F0009-0007-0829-6474",{"EN":735},"Jin Niu",{"VOID":737},"A5054993590",{"id":739,"sortIndex":740,"researcher":24,"roles":741,"affiliations":742,"properties":751,"displayName":755,"givenName":24,"familyName":24},"145acb13-bcfe-4d4e-ab78-50cdb77b4eee",9,[],[743],{"id":744,"sortIndex":25,"affiliation":745,"properties":24},"a83644be-163e-48a9-bd4d-4887dd0f12b1",{"id":744,"createTime":24,"updateTime":24,"relativeEntities":746,"slug":24,"properties":747,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":750,"statistic":24},[],{"title":748},{"EN":749},"Department of Diagnostic Radiology, Dalhousie University, and Nova Scotia Breast Screening Program, Halifax, NS, Canada",[],{"orcid":752,"title":754,"openalex":756},{"VOID":753},"https:\u002F\u002Forcid.org\u002F0000-0001-9565-3685",{"EN":755},"Jennifer Payne",{"VOID":757},"A5021242676",{"id":759,"sortIndex":236,"researcher":24,"roles":760,"affiliations":761,"properties":768,"displayName":772,"givenName":24,"familyName":24},"8c55f20f-0edc-4a71-8a7a-1ece1cdc9765",[],[762],{"id":564,"sortIndex":25,"affiliation":763,"properties":24},{"id":564,"createTime":24,"updateTime":24,"relativeEntities":764,"slug":24,"properties":765,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":767,"statistic":24},[],{"title":766},{"VI":569},[],{"orcid":769,"title":771,"openalex":773},{"VOID":770},"https:\u002F\u002Forcid.org\u002F0009-0003-4250-3255",{"EN":772},"N. K. Shukla",{"VOID":774},"A5056782240",{"url":24,"publisher":776,"properties":814},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":777,"slug":10,"properties":778,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":783,"manageAffiliations":788,"indexDatabases":799,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":779,"eissn":780,"issn":781,"title":782},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[784],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":785,"label":786,"description":787,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[789,794],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":790,"slug":24,"properties":791,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":793,"statistic":24},[],{"title":792},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":795,"slug":24,"properties":796,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":798,"statistic":24},[],{"title":797},{"EN":46},[],[800,807],{"id":50,"indexDatabase":801,"url":61,"indexYears":62,"academicFieldIds":806,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":802,"label":803,"description":804,"key":58,"publicationTags":805,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":808,"url":80,"indexYears":24,"academicFieldIds":813,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":809,"label":810,"description":811,"key":76,"publicationTags":812,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":815,"pages":817,"volume":819},{"VOID":816},"4",{"VOID":818},"297-302",{"VOID":86},{"total":722,"publishYear":24,"statisticByYear":821},{"2018":129,"2019":163,"2021":129,"2022":129,"2023":129,"2024":129},[],[],{"id":825,"createTime":826,"updateTime":826,"relativeEntities":827,"slug":828,"properties":829,"entityType":101,"verifyStatus":102,"verifyTime":844,"verifyNote":104,"languages":845,"translateLanguages":24,"viewCount":25,"primaryUrl":846,"fullTextUrl":24,"authors":847,"publicationType":189,"publisherRelationship":920,"citationCount":965,"citationInfo":966,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":973,"openAccess":24,"references":974,"isForceReanalyzing":244},"1b823d99-95bf-454f-be9e-471ddafe41b1","2024-12-25T17:20:15.774+00:00",[],"Survival-of-Patients-with-Non-Small-Cell-Lung-Cancer-after-a-Diagnosis-of-Brain-Metastases",{"mag":830,"pmc":832,"openalex":834,"abstract":836,"title":838,"pm":840,"doi":842},{"VOID":831},"1964127544",{"VOID":833},"3728058",{"VOID":835},"W1964127544",{"EN":837},"\u003Cjats:p>Background: The prognosis of patients with brain metastases from non-small-cell lung cancer (NSCLC) is poor. However, some reports suggest that patients with brain metastases at the time of initial diagnosis have a more favourable survival than do patients with advanced NSCLC without brain metastases. Methods: In a retrospective cohort of all new lung cancer patients seen at a Canadian tertiary centre between July 2005 and June 2007, we examined survival after a diagnosis of brain metastases for patients with brain metastases at initial diagnosis and patients who developed brain metastases later in their illness. Results: During the 2-year period, 91 of 878 patients (10.4%) developed brain metastases. Median age in this cohort was 64 years. In 45, brain metastases were present at initial diagnosis, and in 46, brain metastases developed later in the course of the illness. Median survival in the entire cohort was 7.8 months. Survival after the diagnosis of brain metastases was similar for patients with brain metastases at diagnosis and later in the illness (4.8 months vs. 3.7 months, p = 0.53). As a result, patients who developed brain metastases later in their illness had a longer overall survival than did patients with brain metastases at diagnosis (9.8 months vs. 4.8 months). Among patients who received chemotherapy, the survival of patients with brain metastases at diagnosis was still poor (6.2 months). Conclusions: Our data show limited survival in patients with brain metastases from NSCLC. Careful patient selection for more aggressive treatment approaches is necessary.\u003C\u002Fjats:p>",{"EN":839},"Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases",{"VOID":841},"23904768",{"VOID":843},"10.3747\u002Fco.20.1481","2024-12-25T17:20:15.773+00:00",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F20\u002F4\u002F1481",[848,867,886,903],{"id":849,"sortIndex":25,"researcher":24,"roles":850,"affiliations":851,"properties":860,"displayName":864,"givenName":24,"familyName":24},"b9f9e02f-28b7-47f3-a205-21ca7d9d9cca",[],[852],{"id":853,"sortIndex":25,"affiliation":854,"properties":24},"338a6c56-d6df-4942-bbd8-33dd126a92a2",{"id":853,"createTime":24,"updateTime":24,"relativeEntities":855,"slug":24,"properties":856,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":859,"statistic":24},[],{"title":857},{"EN":858},"Comprehensive Cancer Centre, King Fahad Medical City, Riyadh, Saudi Arabia.",[],{"orcid":861,"title":863,"openalex":865},{"VOID":862},"https:\u002F\u002Forcid.org\u002F0000-0002-3801-0269",{"EN":864},"Arwa Ali",{"VOID":866},"A5078886680",{"id":868,"sortIndex":129,"researcher":24,"roles":869,"affiliations":870,"properties":879,"displayName":883,"givenName":24,"familyName":24},"4fea2505-469d-4fbf-9209-ba267e116210",[],[871],{"id":872,"sortIndex":25,"affiliation":873,"properties":24},"869833dc-e49b-4644-a94e-0e0025d9bac8",{"id":872,"createTime":24,"updateTime":24,"relativeEntities":874,"slug":24,"properties":875,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":878,"statistic":24},[],{"title":876},{"EN":877},"McMaster university#TAB#",[],{"orcid":880,"title":882,"openalex":884},{"VOID":881},"https:\u002F\u002Forcid.org\u002F0000-0003-1696-8342",{"EN":883},"John R. Goffin",{"VOID":885},"A5052726533",{"id":887,"sortIndex":145,"researcher":24,"roles":888,"affiliations":889,"properties":896,"displayName":900,"givenName":24,"familyName":24},"3820c3ec-e053-4a4b-964c-dd41a714afd3",[],[890],{"id":872,"sortIndex":25,"affiliation":891,"properties":24},{"id":872,"createTime":24,"updateTime":24,"relativeEntities":892,"slug":24,"properties":893,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":895,"statistic":24},[],{"title":894},{"EN":877},[],{"orcid":897,"title":899,"openalex":901},{"VOID":898},"https:\u002F\u002Forcid.org\u002F0000-0002-8821-8527",{"EN":900},"Andrew Arnold",{"VOID":902},"A5049232174",{"id":904,"sortIndex":163,"researcher":24,"roles":905,"affiliations":906,"properties":913,"displayName":917,"givenName":24,"familyName":24},"2d7f26f7-384c-41f6-896b-2926e4f4147e",[],[907],{"id":872,"sortIndex":25,"affiliation":908,"properties":24},{"id":872,"createTime":24,"updateTime":24,"relativeEntities":909,"slug":24,"properties":910,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":912,"statistic":24},[],{"title":911},{"EN":877},[],{"orcid":914,"title":916,"openalex":918},{"VOID":915},"https:\u002F\u002Forcid.org\u002F0000-0003-1590-2130",{"EN":917},"Peter Ellis",{"VOID":919},"A5057361837",{"url":24,"publisher":921,"properties":959},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":922,"slug":10,"properties":923,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":928,"manageAffiliations":933,"indexDatabases":944,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":924,"eissn":925,"issn":926,"title":927},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[929],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":930,"label":931,"description":932,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[934,939],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":935,"slug":24,"properties":936,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":938,"statistic":24},[],{"title":937},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":940,"slug":24,"properties":941,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":943,"statistic":24},[],{"title":942},{"EN":46},[],[945,952],{"id":50,"indexDatabase":946,"url":61,"indexYears":62,"academicFieldIds":951,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":947,"label":948,"description":949,"key":58,"publicationTags":950,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":953,"url":80,"indexYears":24,"academicFieldIds":958,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":954,"label":955,"description":956,"key":76,"publicationTags":957,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":960,"pages":961,"volume":963},{"VOID":816},{"VOID":962},"300-306",{"VOID":964},"20",206,{"total":965,"publishYear":24,"statisticByYear":967},{"2014":163,"2015":177,"2016":531,"2017":722,"2018":968,"2019":531,"2020":969,"2021":969,"2022":970,"2023":971,"2024":972},13,31,32,34,20,[],[],{"id":976,"createTime":977,"updateTime":977,"relativeEntities":978,"slug":979,"properties":980,"entityType":101,"verifyStatus":102,"verifyTime":993,"verifyNote":104,"languages":994,"translateLanguages":24,"viewCount":25,"primaryUrl":995,"fullTextUrl":24,"authors":996,"publicationType":189,"publisherRelationship":1065,"citationCount":163,"citationInfo":1111,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":1113,"openAccess":24,"references":1114,"isForceReanalyzing":244},"ffe46924-ee1c-4b3d-85ce-ce4c0135b975","2024-12-06T02:10:56.016+00:00",[],"Prostate-Cancer-Metastasis-to-the-Pituitary-Gland-Manifesting-as-Corticosteroid-Withdrawal-and-the-Impact-of-the-Switch-from-Prednisone-to-Dexamethasone-on-Survival-Time",{"openalex":981,"mag":983,"abstract":985,"title":987,"pm":989,"doi":991},{"VOID":982},"W3211226672",{"VOID":984},"3211226672",{"EN":986},"\u003Cjats:p>Despite improvements in the diagnosis and treatment of cancers, the incidence of pituitary metastasis has increased. Prostate cancer metastasis to the pituitary, however, is rare, and these tumors usually grow rapidly. They are also more likely to be located in the posterior pituitary, and the presenting symptoms are often nonspecific, which makes early diagnosis challenging. The management of this condition is usually multidisciplinary, and requires careful assessment and decision making. We present a case of a patient who developed prostate cancer metastasis to the pituitary. In this report, we show that patients with prostate cancer on corticosteroid therapy who develop withdrawal symptoms or other endocrine symptoms should be assessed for pituitary and other brain metastasis. This case report also discusses the impact of switching from prednisone and abiraterone to dexamethasone and abiraterone. Our report shows that patients on abiraterone and prednisone whose PSA has increased, but who have no radiologic progression, may have their PSA controlled and thereby improved survival time when they are switched to abiraterone and dexamethasone.\u003C\u002Fjats:p>",{"EN":988},"Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time",{"VOID":990},"34898537",{"VOID":992},"10.3390\u002Fcurroncol28060365","2024-12-06T02:10:56.015+00:00",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F28\u002F6\u002F365",[997,1016,1035,1050],{"id":998,"sortIndex":25,"researcher":24,"roles":999,"affiliations":1000,"properties":1009,"displayName":1013,"givenName":24,"familyName":24},"d234364f-9036-4f34-8dd2-92e6b1e9c96b",[],[1001],{"id":1002,"sortIndex":25,"affiliation":1003,"properties":24},"01dee8c6-878b-4a03-a74f-44e4501b59c7",{"id":1002,"createTime":24,"updateTime":24,"relativeEntities":1004,"slug":24,"properties":1005,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1008,"statistic":24},[],{"title":1006},{"EN":1007},"Oncology Clinical Trials, Horizon Health Network—The Moncton Hospital, Moncton, NB E1C 6Z8, Canada",[],{"orcid":1010,"title":1012,"openalex":1014},{"VOID":1011},"https:\u002F\u002Forcid.org\u002F0000-0002-4389-6738",{"EN":1013},"Okeroghene Ataikiru",{"VOID":1015},"A5051690324",{"id":1017,"sortIndex":129,"researcher":24,"roles":1018,"affiliations":1019,"properties":1028,"displayName":1032,"givenName":24,"familyName":24},"b75dd4c6-27b2-4497-a979-a6dc5931eff5",[],[1020],{"id":1021,"sortIndex":25,"affiliation":1022,"properties":24},"903c8c18-8c51-42e2-b1a5-fa4164e8afea",{"id":1021,"createTime":24,"updateTime":24,"relativeEntities":1023,"slug":24,"properties":1024,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1027,"statistic":24},[],{"title":1025},{"EN":1026},"Oncology and Hematology Division, Horizon Health Network—The Moncton Hospital, Moncton, NB E1C 6Z8, Canada",[],{"orcid":1029,"title":1031,"openalex":1033},{"VOID":1030},"https:\u002F\u002Forcid.org\u002F0000-0002-6879-1107",{"EN":1032},"Mahmoud Abdelsalam",{"VOID":1034},"A5006682340",{"id":1036,"sortIndex":145,"researcher":24,"roles":1037,"affiliations":1038,"properties":1045,"displayName":1047,"givenName":24,"familyName":24},"8189f28d-b3b4-4bec-ba55-824ad0ef8153",[],[1039],{"id":1002,"sortIndex":25,"affiliation":1040,"properties":24},{"id":1002,"createTime":24,"updateTime":24,"relativeEntities":1041,"slug":24,"properties":1042,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1044,"statistic":24},[],{"title":1043},{"EN":1007},[],{"title":1046,"openalex":1048},{"EN":1047},"Mrudula Avileli",{"VOID":1049},"A5072666753",{"id":1051,"sortIndex":163,"researcher":24,"roles":1052,"affiliations":1053,"properties":1060,"displayName":1062,"givenName":24,"familyName":24},"aa9708eb-b036-43de-83a1-93de3675895b",[],[1054],{"id":1002,"sortIndex":25,"affiliation":1055,"properties":24},{"id":1002,"createTime":24,"updateTime":24,"relativeEntities":1056,"slug":24,"properties":1057,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1059,"statistic":24},[],{"title":1058},{"EN":1007},[],{"title":1061,"openalex":1063},{"EN":1062},"T V HYNES",{"VOID":1064},"A5074116512",{"url":24,"publisher":1066,"properties":1104},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1067,"slug":10,"properties":1068,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":1073,"manageAffiliations":1078,"indexDatabases":1089,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":1069,"eissn":1070,"issn":1071,"title":1072},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[1074],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":1075,"label":1076,"description":1077,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[1079,1084],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":1080,"slug":24,"properties":1081,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1083,"statistic":24},[],{"title":1082},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":1085,"slug":24,"properties":1086,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1088,"statistic":24},[],{"title":1087},{"EN":46},[],[1090,1097],{"id":50,"indexDatabase":1091,"url":61,"indexYears":62,"academicFieldIds":1096,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":1092,"label":1093,"description":1094,"key":58,"publicationTags":1095,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":1098,"url":80,"indexYears":24,"academicFieldIds":1103,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":1099,"label":1100,"description":1101,"key":76,"publicationTags":1102,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":1105,"pages":1107,"volume":1109},{"VOID":1106},"6",{"VOID":1108},"4291-4297",{"VOID":1110},"28",{"total":163,"publishYear":24,"statisticByYear":1112},{"2021":129,"2022":129,"2023":129},[],[1115,1119,1123,1127,1131,1134,1138,1142,1146,1150],{"id":24,"text":1116,"url":24,"identifiers":1117},"Javanbakht, 2018, Pituitary metastasis: A rare condition, Endocr. Connect, 7, 1049, 10.1530\u002FEC-18-0338",{"doi":1118},"10.1530\u002FEC-18-0338",{"id":24,"text":1120,"url":24,"identifiers":1121},"Ng, 2020, Current status and treatment modalities in metastases to the pituitary: A systematic review, J. Neurooncol., 146, 219, 10.1007\u002Fs11060-020-03396-w",{"doi":1122},"10.1007\u002Fs11060-020-03396-w",{"id":24,"text":1124,"url":24,"identifiers":1125},"Lozano, 2018, Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study), Br. J. Cancer, 119, 1052, 10.1038\u002Fs41416-018-0123-9",{"doi":1126},"10.1038\u002Fs41416-018-0123-9",{"id":24,"text":1128,"url":24,"identifiers":1129},"Patel, 2003, Rare case of metastatic prostate adenocarcinoma to the pituitary, Urology, 62, 352, 10.1016\u002FS0090-4295(03)00367-4",{"doi":1130},"10.1016\u002FS0090-4295(03)00367-4",{"id":24,"text":1132,"url":24,"identifiers":1133},"Zadravec, 2015, Initial symptomatic pituitary metastasis in a patient with prostate foamy gland carcinoma: Tailoring safe and effective therapy, Acta Clin. Croat., 54, 243",{},{"id":24,"text":1135,"url":24,"identifiers":1136},"Dias, 2018, Pituitary and other sellar region metastases, Curr. Opin. Endocr. Metab. Res., 1, 36, 10.1016\u002Fj.coemr.2018.05.001",{"doi":1137},"10.1016\u002Fj.coemr.2018.05.001",{"id":24,"text":1139,"url":24,"identifiers":1140},"Yılmaz, H., Kaya, M., Can, M., Ozbek, M., and Keyik, B. (2012). Metastatic prostate adenocarcinoma presenting central diabetes insipidus. Case Rep. Med., 2012.",{"doi":1141},"10.1155\u002F2012\u002F452149",{"id":24,"text":1143,"url":24,"identifiers":1144},"Komninos, 2004, Tumors metastatic to the pituitary gland: Case report and literature review, J. Clin. Endocrinol. Metab., 89, 574, 10.1210\u002Fjc.2003-030395",{"doi":1145},"10.1210\u002Fjc.2003-030395",{"id":24,"text":1147,"url":24,"identifiers":1148},"Lithgow, 2020, Pituitary metastases: Presentation and outcomes from a pituitary center over the last decade, Pituitary, 23, 258, 10.1007\u002Fs11102-020-01034-2",{"doi":1149},"10.1007\u002Fs11102-020-01034-2",{"id":24,"text":1151,"url":24,"identifiers":1152},"Nolan, 2001, Anterior pituitary trophic responses to dexamethasone withdrawal and repeated dexamethasone exposures, J. Endocrinol., 169, 263, 10.1677\u002Fjoe.0.1690263",{"doi":1153},"10.1677\u002Fjoe.0.1690263",{"id":1155,"createTime":1156,"updateTime":1156,"relativeEntities":1157,"slug":1158,"properties":1159,"entityType":101,"verifyStatus":102,"verifyTime":1156,"verifyNote":104,"languages":1174,"translateLanguages":24,"viewCount":25,"primaryUrl":1175,"fullTextUrl":24,"authors":1176,"publicationType":189,"publisherRelationship":1211,"citationCount":1255,"citationInfo":1256,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":1259,"openAccess":24,"references":1260,"isForceReanalyzing":244},"f3672a62-db0c-4127-bb30-24c36cf46f90","2024-12-05T04:04:39.300+00:00",[],"Multidisciplinary-Management-of-Cancer-Patients-Chasing-a-Shadow-or-Real-Value-An-Overview-of-the-Literature",{"mag":1160,"pmc":1162,"openalex":1164,"abstract":1166,"title":1168,"pm":1170,"doi":1172},{"VOID":1161},"2079455727",{"VOID":1163},"3410834",{"VOID":1165},"W2079455727",{"EN":1167},"\u003Cjats:p>Purpose: Multidisciplinary cancer conferences (mccs) are designed to optimize patient outcomes. It appears intuitive that mccs are essential to clinical decision-making and patient management; however, it is unclear whether that belief is supported by evidence. Our objectives were to assess the currently published literature addressing the impact of mccs on clinical decision-making and patient outcomes. Methods: Ovid medline was searched from 1950 to June 2010 using these keywords: “multidisciplinary\u002Finterdisciplinary\u002Fclinical meeting$\u002Fconference$\u002Fround$\u002Fteam$,” “decision making,” “neoplasms$\u002Fcancer$\u002Foncology\u002Ftumo(u)r conference$\u002Fboard$\u002Fmeeting$,” “multidisciplinary\u002Finterdisciplinary cancer conference$\u002Fmeeting$.” All trials, guidelines, metaanalyses, reviews, and prospective and retrospective studies were included. Results: The keywords retrieved 595 abstracts, and 30 manuscripts were obtained. Most of the studies assessed the impact of mccs on clinical decision-making rather than on patient outcomes. Conclusions: Available evidence supports the belief that mccs significantly influence clinical decision-making and treatment recommendations. In contrast, scant evidence suggests that mccs improve patient outcomes. Unfortunately, the current literature is substantially heterogeneous and therefore does not allow for firm conclusions.\u003C\u002Fjats:p>",{"EN":1169},"Multidisciplinary Management of Cancer Patients: Chasing a Shadow or Real Value? An Overview of the Literature",{"VOID":1171},"22876151",{"VOID":1173},"10.3747\u002Fco.19.944",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F19\u002F4\u002F944",[1177,1196],{"id":1178,"sortIndex":25,"researcher":24,"roles":1179,"affiliations":1180,"properties":1189,"displayName":1193,"givenName":24,"familyName":24},"66dd3342-4798-457b-8746-27b0388b5f4f",[],[1181],{"id":1182,"sortIndex":25,"affiliation":1183,"properties":24},"0a198f9a-b3a4-4c8c-81ad-ae21b5789fa6",{"id":1182,"createTime":24,"updateTime":24,"relativeEntities":1184,"slug":24,"properties":1185,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1188,"statistic":24},[],{"title":1186},{"EN":1187},"Department of Radiation Oncology, The Ottawa Hospital, University of Ottawa",[],{"orcid":1190,"title":1192,"openalex":1194},{"VOID":1191},"https:\u002F\u002Forcid.org\u002F0000-0002-7090-6313",{"EN":1193},"Jennifer Croke",{"VOID":1195},"A5032770101",{"id":1197,"sortIndex":129,"researcher":24,"roles":1198,"affiliations":1199,"properties":1206,"displayName":1208,"givenName":24,"familyName":24},"015f928c-bd62-4f3f-baed-d9a49673ae1e",[],[1200],{"id":1182,"sortIndex":25,"affiliation":1201,"properties":24},{"id":1182,"createTime":24,"updateTime":24,"relativeEntities":1202,"slug":24,"properties":1203,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1205,"statistic":24},[],{"title":1204},{"EN":1187},[],{"title":1207,"openalex":1209},{"EN":1208},"S. El-Sayed",{"VOID":1210},"A5112393716",{"url":24,"publisher":1212,"properties":1250},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1213,"slug":10,"properties":1214,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":1219,"manageAffiliations":1224,"indexDatabases":1235,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":1215,"eissn":1216,"issn":1217,"title":1218},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[1220],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":1221,"label":1222,"description":1223,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[1225,1230],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":1226,"slug":24,"properties":1227,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1229,"statistic":24},[],{"title":1228},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":1231,"slug":24,"properties":1232,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1234,"statistic":24},[],{"title":1233},{"EN":46},[],[1236,1243],{"id":50,"indexDatabase":1237,"url":61,"indexYears":62,"academicFieldIds":1242,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":1238,"label":1239,"description":1240,"key":58,"publicationTags":1241,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":1244,"url":80,"indexYears":24,"academicFieldIds":1249,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":1245,"label":1246,"description":1247,"key":76,"publicationTags":1248,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":1251,"pages":1252,"volume":1254},{"VOID":816},{"VOID":1253},"232-238",{"VOID":361},101,{"total":1255,"publishYear":24,"statisticByYear":1257},{"2012":129,"2013":666,"2014":686,"2015":722,"2016":702,"2017":666,"2018":702,"2019":722,"2020":362,"2021":531,"2022":702,"2023":1258,"2024":686},11,[],[],{"id":1262,"createTime":1263,"updateTime":1263,"relativeEntities":1264,"slug":1265,"properties":1266,"entityType":101,"verifyStatus":102,"verifyTime":1263,"verifyNote":104,"languages":1281,"translateLanguages":24,"viewCount":25,"primaryUrl":1282,"fullTextUrl":24,"authors":1283,"publicationType":189,"publisherRelationship":1378,"citationCount":666,"citationInfo":1423,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":1425,"openAccess":24,"references":1426,"isForceReanalyzing":244},"2afc26ef-73e4-4f1f-9f82-d4f9307e3496","2024-12-02T15:15:53.258+00:00",[],"Factors-Affecting-Radiotherapy-Prescribing-Patterns-in-the-Post-Mastectomy-Setting",{"mag":1267,"pmc":1269,"openalex":1271,"abstract":1273,"title":1275,"pm":1277,"doi":1279},{"VOID":1268},"2801805932",{"VOID":1270},"5927794",{"VOID":1272},"W2801805932",{"EN":1274},"\u003Cjats:p>Background: Radiation therapy (RT) after mastectomy for breast cancer can improve survival outcomes, but has been associated with inferior cosmesis after breast reconstruction. In the literature, RT dose and fractionation schedules are inconsistently reported. We sought to determine the pattern of RT prescribing practices in a provincial RT program for patients treated with mastectomy and reconstruction. Methods: Women diagnosed with stages 0–III breast cancer between January 2012 and December 2013 and treated with curative-intent rt were identified from a clinicopathology database. Patient demographic, tumour, and treatment information were extracted. Of the identified patients, those undergoing mastectomy were the focus of the present analysis. Results: Of 4016 patients identified, 1143 (28%) underwent mastectomy. The patients treated with mastectomy had a median age of 57 years, and 37% of them underwent reconstruction. Treatment with more than 16 fractions of rt was associated with autologous reconstruction [odds ratio (OR): 37.2; 95% confidence interval (CI): 11.2 to 123.7; p < 0.001], implant reconstruction (OR: 93.3; 95% CI: 45.3 to 192.2; p < 0.001), and treating centre. Hypofractionated treatment was associated with older age (OR: 0.94; 95% CI: 0.92 to 0.96; p < 0.001), and living more than 400 km from a treatment centre (OR: 0.37; 95% CI: 0.16 to 0.86; p = 0.02). Conclusions: Prescribing practices in breast cancer patients undergoing mastectomy are influenced by reconstruction intent, age, nodal status, and distance from the treatment centre. Those factors should be considered when making treatment decisions.\u003C\u002Fjats:p>",{"EN":1276},"Factors Affecting Radiotherapy Prescribing Patterns in the Post-Mastectomy Setting",{"VOID":1278},"29719439",{"VOID":1280},"10.3747\u002Fco.25.3773",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F25\u002F2\u002F3773",[1284,1317,1336,1355],{"id":1285,"sortIndex":25,"researcher":24,"roles":1286,"affiliations":1287,"properties":1312,"displayName":1314,"givenName":24,"familyName":24},"47b85293-edb9-4de0-958c-da0120ba2800",[],[1288,1296,1304],{"id":1289,"sortIndex":25,"affiliation":1290,"properties":24},"3ee1d36f-91bf-4748-a587-3ce6b39c359f",{"id":1289,"createTime":24,"updateTime":24,"relativeEntities":1291,"slug":24,"properties":1292,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1295,"statistic":24},[],{"title":1293},{"EN":1294},"BC Canc Ctr North, Dept Radiat Oncol, Prince George, BC, Canada",[],{"id":1297,"sortIndex":129,"affiliation":1298,"properties":24},"fd815e85-b5ea-4f22-a570-236e20484509",{"id":1297,"createTime":24,"updateTime":24,"relativeEntities":1299,"slug":24,"properties":1300,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1303,"statistic":24},[],{"title":1301},{"EN":1302},"BC Canc Sindi Ahluwalia Hawkins Ctr Southern Inte, Dept Radiat Oncol, Kelowna, BC, Canada",[],{"id":1305,"sortIndex":145,"affiliation":1306,"properties":24},"16e95e8a-2ab6-4b3b-bc88-fd89e37b3e88",{"id":1305,"createTime":24,"updateTime":24,"relativeEntities":1307,"slug":24,"properties":1308,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1311,"statistic":24},[],{"title":1309},{"EN":1310},"Univ British Columbia, Dept Surg, Vancouver, BC, Canada",[],{"title":1313,"openalex":1315},{"EN":1314},"Theodora Koulis",{"VOID":1316},"A5004915353",{"id":1318,"sortIndex":129,"researcher":24,"roles":1319,"affiliations":1320,"properties":1329,"displayName":1333,"givenName":24,"familyName":24},"f3b448b8-e449-4cd3-9116-2c1db50ea0e0",[],[1321],{"id":1322,"sortIndex":25,"affiliation":1323,"properties":24},"3eb1c413-3ed9-4127-98f9-857fba38b3b9",{"id":1322,"createTime":24,"updateTime":24,"relativeEntities":1324,"slug":24,"properties":1325,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1328,"statistic":24},[],{"title":1326},{"EN":1327},"Univ British Columbia, Sch Med, Prince George, BC, Canada",[],{"orcid":1330,"title":1332,"openalex":1334},{"VOID":1331},"https:\u002F\u002Forcid.org\u002F0000-0001-7001-8511",{"EN":1333},"Amit Dang",{"VOID":1335},"A5013065378",{"id":1337,"sortIndex":145,"researcher":24,"roles":1338,"affiliations":1339,"properties":1348,"displayName":1352,"givenName":24,"familyName":24},"b3a3a8a0-c7b9-4e48-9823-e3f01951352d",[],[1340],{"id":1341,"sortIndex":25,"affiliation":1342,"properties":24},"4f0a9481-c1d2-4187-866a-b484e4477cbd",{"id":1341,"createTime":24,"updateTime":24,"relativeEntities":1343,"slug":24,"properties":1344,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1347,"statistic":24},[],{"title":1345},{"EN":1346},"Vancouver Ctr, BC Canc Breast Canc Outcomes Unit, Vancouver, BC, Canada",[],{"orcid":1349,"title":1351,"openalex":1353},{"VOID":1350},"https:\u002F\u002Forcid.org\u002F0000-0003-2361-4681",{"EN":1352},"Caroline Speers",{"VOID":1354},"A5079451746",{"id":1356,"sortIndex":163,"researcher":24,"roles":1357,"affiliations":1358,"properties":1371,"displayName":1375,"givenName":24,"familyName":24},"637e3d5f-a2dd-477a-8cc3-a9625b013c25",[],[1359,1365],{"id":1289,"sortIndex":25,"affiliation":1360,"properties":24},{"id":1289,"createTime":24,"updateTime":24,"relativeEntities":1361,"slug":24,"properties":1362,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1364,"statistic":24},[],{"title":1363},{"EN":1294},[],{"id":1305,"sortIndex":129,"affiliation":1366,"properties":24},{"id":1305,"createTime":24,"updateTime":24,"relativeEntities":1367,"slug":24,"properties":1368,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1370,"statistic":24},[],{"title":1369},{"EN":1310},[],{"orcid":1372,"title":1374,"openalex":1376},{"VOID":1373},"https:\u002F\u002Forcid.org\u002F0000-0003-4532-6197",{"EN":1375},"Robert Olson",{"VOID":1377},"A5101670641",{"url":24,"publisher":1379,"properties":1417},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1380,"slug":10,"properties":1381,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":1386,"manageAffiliations":1391,"indexDatabases":1402,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":1382,"eissn":1383,"issn":1384,"title":1385},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[1387],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":1388,"label":1389,"description":1390,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[1392,1397],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":1393,"slug":24,"properties":1394,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1396,"statistic":24},[],{"title":1395},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":1398,"slug":24,"properties":1399,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1401,"statistic":24},[],{"title":1400},{"EN":46},[],[1403,1410],{"id":50,"indexDatabase":1404,"url":61,"indexYears":62,"academicFieldIds":1409,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":1405,"label":1406,"description":1407,"key":58,"publicationTags":1408,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":1411,"url":80,"indexYears":24,"academicFieldIds":1416,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":1412,"label":1413,"description":1414,"key":76,"publicationTags":1415,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":1418,"pages":1419,"volume":1421},{"VOID":357},{"VOID":1420},"146-151",{"VOID":1422},"25",{"total":666,"publishYear":24,"statisticByYear":1424},{"2018":129,"2019":129,"2020":145,"2021":129},[],[],{"id":1428,"createTime":1429,"updateTime":1429,"relativeEntities":1430,"slug":1431,"properties":1432,"entityType":101,"verifyStatus":102,"verifyTime":1429,"verifyNote":104,"languages":1447,"translateLanguages":24,"viewCount":25,"primaryUrl":1448,"fullTextUrl":24,"authors":1449,"publicationType":189,"publisherRelationship":1507,"citationCount":1551,"citationInfo":1552,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":1555,"openAccess":24,"references":1556,"isForceReanalyzing":244},"c8055e05-f2be-442b-9218-266da107316a","2024-11-28T05:24:23.489+00:00",[],"A-Systematic-Review-of-Acupuncture-for-Chemotherapy-Induced-Peripheral-Neuropathy",{"mag":1433,"pmc":1435,"openalex":1437,"abstract":1439,"title":1441,"pm":1443,"doi":1445},{"VOID":1434},"2942660786",{"VOID":1436},"6476456",{"VOID":1438},"W2942660786",{"EN":1440},"\u003Cjats:p>Objectives: In cancer patients, chemotherapy-induced peripheral neuropathy (cipn) is a common complication, characterized by pain, loss of sensation, and numbness. Medical treatment for peripheral neuropathies has been shown to be ineffective for cipn. Acupuncture has been shown to be safe and effective in treating cancer-related symptoms and other peripheral neuropathies. For the present review, we aimed to evaluate the efficacy of acupuncture for the treatment of cipn. Design: Comprehensive searches for relevant studies were conducted in Ovid embase, the Web of Science, Ovid medline, the Cochrane Central Register of Controlled Trials (central), cinahl (ebsco Information Services, Ipswich, MA, U.S.A.), and the ClinicalTrials.gov Web site. References from previous systematic reviews were also searched. Additional trials were found in the reference lists of relevant papers and in searches of Google Scholar and acupuncturespecific Web sites. Included studies were randomized controlled trials (rcts) of any type of acupuncture used to treat patients with cipn. Results: Three clinical trials (203 participants) were included. Two studies found acupuncture to be effective in alleviating cipn pain and improving quality of life. One study found no benefit in improving neuropathic pain, symptoms, or quality of life. Study quality was variable and included a moderate overall risk of bias. Conclusions: The evidence is insufficient to recommend acupuncture for the treatment or prevention of cipn. Further research is needed to evaluate the effects of acupuncture in the treatment of cipn. Given that acupuncture is considered safe and might provide relief for patients, it can be considered at the clinician’s discretion.\u003C\u002Fjats:p>",{"EN":1442},"A Systematic Review of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy",{"VOID":1444},"31043820",{"VOID":1446},"10.3747\u002Fco.26.4261",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F26\u002F2\u002F4261",[1450,1469,1488],{"id":1451,"sortIndex":25,"researcher":24,"roles":1452,"affiliations":1453,"properties":1462,"displayName":1466,"givenName":24,"familyName":24},"0938390b-388a-44a0-bd2a-a71b4f24c69a",[],[1454],{"id":1455,"sortIndex":25,"affiliation":1456,"properties":24},"c02705d4-1784-4053-8e4e-a8a6d09d0fb6",{"id":1455,"createTime":24,"updateTime":24,"relativeEntities":1457,"slug":24,"properties":1458,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1461,"statistic":24},[],{"title":1459},{"VI":1460},"Faculty of Medicine, University of British Columbia, 317 – 2194 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada",[],{"orcid":1463,"title":1465,"openalex":1467},{"VOID":1464},"https:\u002F\u002Forcid.org\u002F0000-0003-0425-2363",{"EN":1466},"Kevin Li",{"VOID":1468},"A5100667672",{"id":1470,"sortIndex":129,"researcher":24,"roles":1471,"affiliations":1472,"properties":1481,"displayName":1485,"givenName":24,"familyName":24},"f6303199-045c-4e4e-bbc5-8828776e2b4b",[],[1473],{"id":1474,"sortIndex":25,"affiliation":1475,"properties":24},"350db9fe-d0da-476b-9a08-b64756babeb8",{"id":1474,"createTime":24,"updateTime":24,"relativeEntities":1476,"slug":24,"properties":1477,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1480,"statistic":24},[],{"title":1478},{"EN":1479},"Biomedical Branch Library, University of British Columbia, Vancouver, BC, Canada",[],{"orcid":1482,"title":1484,"openalex":1486},{"VOID":1483},"https:\u002F\u002Forcid.org\u002F0000-0002-6197-8788",{"EN":1485},"Dean Giustini",{"VOID":1487},"A5060127477",{"id":1489,"sortIndex":145,"researcher":24,"roles":1490,"affiliations":1491,"properties":1500,"displayName":1504,"givenName":24,"familyName":24},"bb41035f-3783-4a34-a57e-17bc70b57705",[],[1492],{"id":1493,"sortIndex":25,"affiliation":1494,"properties":24},"c2e59522-7bc1-4338-9ce7-163e5a13f535",{"id":1493,"createTime":24,"updateTime":24,"relativeEntities":1495,"slug":24,"properties":1496,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1499,"statistic":24},[],{"title":1497},{"EN":1498},"Ottawa Integrative Cancer Centre, Ottawa, ON, Canada",[],{"orcid":1501,"title":1503,"openalex":1505},{"VOID":1502},"https:\u002F\u002Forcid.org\u002F0000-0003-4893-5254",{"EN":1504},"Dugald Seely",{"VOID":1506},"A5057397030",{"url":24,"publisher":1508,"properties":1546},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1509,"slug":10,"properties":1510,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":1515,"manageAffiliations":1520,"indexDatabases":1531,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":1511,"eissn":1512,"issn":1513,"title":1514},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[1516],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":1517,"label":1518,"description":1519,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[1521,1526],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":1522,"slug":24,"properties":1523,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1525,"statistic":24},[],{"title":1524},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":1527,"slug":24,"properties":1528,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1530,"statistic":24},[],{"title":1529},{"EN":46},[],[1532,1539],{"id":50,"indexDatabase":1533,"url":61,"indexYears":62,"academicFieldIds":1538,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":1534,"label":1535,"description":1536,"key":58,"publicationTags":1537,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":1540,"url":80,"indexYears":24,"academicFieldIds":1545,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":1541,"label":1542,"description":1543,"key":76,"publicationTags":1544,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":1547,"pages":1548,"volume":1550},{"VOID":357},{"VOID":1549},"4261",{"VOID":530},57,{"total":1551,"publishYear":24,"statisticByYear":1553},{"2019":722,"2020":686,"2021":968,"2022":1554,"2023":236,"2024":722},12,[],[],{"id":1558,"createTime":1559,"updateTime":1559,"relativeEntities":1560,"slug":1561,"properties":1562,"entityType":101,"verifyStatus":102,"verifyTime":1559,"verifyNote":104,"languages":1573,"translateLanguages":24,"viewCount":25,"primaryUrl":1574,"fullTextUrl":24,"authors":1575,"publicationType":189,"publisherRelationship":1743,"citationCount":1789,"citationInfo":1790,"publishDate":24,"publishYear":24,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":1795,"openAccess":24,"references":1796,"isForceReanalyzing":244},"cca4ebd6-80ae-4428-838a-787b204e0c43","2024-10-10T11:01:51.514+00:00",[],"Immune-Checkpoint-Inhibitors-in-Cancer-Therapy",{"openalex":1563,"abstract":1565,"title":1567,"pm":1569,"doi":1571},{"VOID":1564},"W4226329559",{"EN":1566},"\u003Cjats:p>The discovery of immune checkpoint proteins such as PD-1\u002FPDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and non-small lung cancer. The US FDA has successfully approved three different categories of immune checkpoint inhibitors (ICIs) such as PD-1 inhibitors (Nivolumab, Pembrolizumab, and Cemiplimab), PDL-1 inhibitors (Atezolimumab, Durvalumab and Avelumab), and CTLA-4 inhibitor (Ipilimumab). Unfortunately, not all patients respond favourably to these drugs, highlighting the role of biomarkers such as Tumour mutation burden (TMB), PDL-1 expression, microbiome, hypoxia, interferon-γ, and ECM in predicting responses to ICIs-based immunotherapy. The current study aims to review the literature and updates on ICIs in cancer therapy.\u003C\u002Fjats:p>",{"EN":1568},"Immune Checkpoint Inhibitors in Cancer Therapy",{"VOID":1570},"35621637",{"VOID":1572},"10.3390\u002Fcurroncol29050247",[106],"https:\u002F\u002Fwww.mdpi.com\u002F1718-7729\u002F29\u002F5\u002F247",[1576,1595,1614,1633,1652,1671,1690,1709,1726],{"id":1577,"sortIndex":25,"researcher":24,"roles":1578,"affiliations":1579,"properties":1588,"displayName":1592,"givenName":24,"familyName":24},"2dc7dfc3-3886-43c1-9f4f-f44b1060a54f",[],[1580],{"id":1581,"sortIndex":25,"affiliation":1582,"properties":24},"6c8fae61-1958-48b7-b3b9-598cc71ebea8",{"id":1581,"createTime":24,"updateTime":24,"relativeEntities":1583,"slug":24,"properties":1584,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1587,"statistic":24},[],{"title":1585},{"VI":1586},"Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, 80138 Naples, Italy",[],{"orcid":1589,"title":1591,"openalex":1593},{"VOID":1590},"https:\u002F\u002Forcid.org\u002F0000-0003-4762-6521",{"EN":1592},"Yavar Shiravand",{"VOID":1594},"A5034919969",{"id":1596,"sortIndex":129,"researcher":24,"roles":1597,"affiliations":1598,"properties":1607,"displayName":1611,"givenName":24,"familyName":24},"a8515ef0-26e7-402c-bd61-722db33c4d41",[],[1599],{"id":1600,"sortIndex":25,"affiliation":1601,"properties":24},"5db2ec70-3ce4-4f2c-9025-ca8f01e8be3e",{"id":1600,"createTime":24,"updateTime":24,"relativeEntities":1602,"slug":24,"properties":1603,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1606,"statistic":24},[],{"title":1604},{"EN":1605},"Faculty of Pharmaceutical Sciences, PES College of Pharmacy, PES University, Bengaluru 560085, India",[],{"orcid":1608,"title":1610,"openalex":1612},{"VOID":1609},"https:\u002F\u002Forcid.org\u002F0000-0002-5720-4333",{"EN":1611},"Faezeh Khodadadi",{"VOID":1613},"A5062589659",{"id":1615,"sortIndex":145,"researcher":24,"roles":1616,"affiliations":1617,"properties":1626,"displayName":1630,"givenName":24,"familyName":24},"27414c55-ff5d-4539-bcf7-c72c601f9a22",[],[1618],{"id":1619,"sortIndex":25,"affiliation":1620,"properties":24},"df3ef23b-0411-4e16-8126-847b95abe2c7",{"id":1619,"createTime":24,"updateTime":24,"relativeEntities":1621,"slug":24,"properties":1622,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1625,"statistic":24},[],{"title":1623},{"EN":1624},"Student Research Committee, Shiraz University of Medical Sciences, Shiraz 7134814336, Iran",[],{"orcid":1627,"title":1629,"openalex":1631},{"VOID":1628},"https:\u002F\u002Forcid.org\u002F0000-0002-9377-5731",{"EN":1630},"Seyyed Mohammad Amin Kashani",{"VOID":1632},"A5068868843",{"id":1634,"sortIndex":163,"researcher":24,"roles":1635,"affiliations":1636,"properties":1645,"displayName":1649,"givenName":24,"familyName":24},"e9209458-972c-4fb8-b23b-8916946f61bc",[],[1637],{"id":1638,"sortIndex":25,"affiliation":1639,"properties":24},"84050d8d-6716-4e75-a992-75e271e12307",{"id":1638,"createTime":24,"updateTime":24,"relativeEntities":1640,"slug":24,"properties":1641,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1644,"statistic":24},[],{"title":1642},{"EN":1643},"Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran",[],{"orcid":1646,"title":1648,"openalex":1650},{"VOID":1647},"https:\u002F\u002Forcid.org\u002F0009-0004-5469-3954",{"EN":1649},"Seyed Reza Hosseini‐Fard",{"VOID":1651},"A5003451104",{"id":1653,"sortIndex":177,"researcher":24,"roles":1654,"affiliations":1655,"properties":1664,"displayName":1668,"givenName":24,"familyName":24},"ce071317-647d-4966-92d7-0143a8ee8221",[],[1656],{"id":1657,"sortIndex":25,"affiliation":1658,"properties":24},"a99d9e09-3262-4ec7-aee9-8e70ebd56b7e",{"id":1657,"createTime":24,"updateTime":24,"relativeEntities":1659,"slug":24,"properties":1660,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1663,"statistic":24},[],{"title":1661},{"EN":1662},"Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj 6617713446, Iran",[],{"orcid":1665,"title":1667,"openalex":1669},{"VOID":1666},"https:\u002F\u002Forcid.org\u002F0000-0001-8008-4838",{"EN":1668},"Shadi Hosseini",{"VOID":1670},"A5072131341",{"id":1672,"sortIndex":666,"researcher":24,"roles":1673,"affiliations":1674,"properties":1683,"displayName":1687,"givenName":24,"familyName":24},"c9502162-567c-49d7-8078-6d3f0bd36065",[],[1675],{"id":1676,"sortIndex":25,"affiliation":1677,"properties":24},"dbb6c4b0-fa9e-41ed-9527-6bce1e79abb4",{"id":1676,"createTime":24,"updateTime":24,"relativeEntities":1678,"slug":24,"properties":1679,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1682,"statistic":24},[],{"title":1680},{"EN":1681},"The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4102, Australia",[],{"orcid":1684,"title":1686,"openalex":1688},{"VOID":1685},"https:\u002F\u002Forcid.org\u002F0000-0002-1919-5958",{"EN":1687},"Habib Sadeghirad",{"VOID":1689},"A5007298069",{"id":1691,"sortIndex":686,"researcher":24,"roles":1692,"affiliations":1693,"properties":1702,"displayName":1706,"givenName":24,"familyName":24},"043e18e2-f448-4e7c-a210-d833c62c8576",[],[1694],{"id":1695,"sortIndex":25,"affiliation":1696,"properties":24},"ecb4acb5-f093-4c52-aa56-d6d0525cd440",{"id":1695,"createTime":24,"updateTime":24,"relativeEntities":1697,"slug":24,"properties":1698,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1701,"statistic":24},[],{"title":1699},{"VI":1700},"Princess Alexandra Hospital, Brisbane, Qld 4102, Australia",[],{"orcid":1703,"title":1705,"openalex":1707},{"VOID":1704},"https:\u002F\u002Forcid.org\u002F0000-0002-4196-0177",{"EN":1706},"Rahul Ladwa",{"VOID":1708},"A5028812401",{"id":1710,"sortIndex":702,"researcher":24,"roles":1711,"affiliations":1712,"properties":1719,"displayName":1723,"givenName":24,"familyName":24},"240cc78c-f20f-4d87-9637-2b6a4136e79e",[],[1713],{"id":1695,"sortIndex":25,"affiliation":1714,"properties":24},{"id":1695,"createTime":24,"updateTime":24,"relativeEntities":1715,"slug":24,"properties":1716,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1718,"statistic":24},[],{"title":1717},{"VI":1700},[],{"orcid":1720,"title":1722,"openalex":1724},{"VOID":1721},"https:\u002F\u002Forcid.org\u002F0000-0002-6754-5633",{"EN":1723},"Kenneth V. Honn",{"VOID":1725},"A5033519199",{"id":1727,"sortIndex":722,"researcher":24,"roles":1728,"affiliations":1729,"properties":1736,"displayName":1740,"givenName":24,"familyName":24},"ad84b510-b939-4377-8914-0fe6b88c66e6",[],[1730],{"id":1676,"sortIndex":25,"affiliation":1731,"properties":24},{"id":1676,"createTime":24,"updateTime":24,"relativeEntities":1732,"slug":24,"properties":1733,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1735,"statistic":24},[],{"title":1734},{"EN":1681},[],{"orcid":1737,"title":1739,"openalex":1741},{"VOID":1738},"https:\u002F\u002Forcid.org\u002F0000-0003-3224-7350",{"EN":1740},"Arutha Kulasinghe",{"VOID":1742},"A5030525901",{"url":24,"publisher":1744,"properties":1782},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1745,"slug":10,"properties":1746,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":1751,"manageAffiliations":1756,"indexDatabases":1767,"url":83,"thumbnailPath":24,"statistic":24,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":1747,"eissn":1748,"issn":1749,"title":1750},{"VOID":13},{"VOID":15},{"VOID":17},{"EN":19},[1752],{"id":28,"createTime":24,"updateTime":24,"relativeEntities":1753,"label":1754,"description":1755,"parentId":24,"standard":24,"scholarHubFieldId":24},[],{"EN":31},{},[1757,1762],{"id":35,"createTime":24,"updateTime":24,"relativeEntities":1758,"slug":24,"properties":1759,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1761,"statistic":24},[],{"title":1760},{"EN":39},[],{"id":42,"createTime":24,"updateTime":24,"relativeEntities":1763,"slug":24,"properties":1764,"entityType":24,"verifyStatus":24,"verifyTime":24,"verifyNote":24,"languages":24,"translateLanguages":24,"viewCount":24,"url":24,"parentIds":1766,"statistic":24},[],{"title":1765},{"EN":46},[],[1768,1775],{"id":50,"indexDatabase":1769,"url":61,"indexYears":62,"academicFieldIds":1774,"indexDatabaseRanking":65},{"id":52,"createTime":24,"updateTime":24,"relativeEntities":1770,"label":1771,"description":1772,"key":58,"publicationTags":1773,"standard":24},[],{"EN":55,"VI":55},{"EN":55,"VI":57},[60],[64],{"id":67,"indexDatabase":1776,"url":80,"indexYears":24,"academicFieldIds":1781,"indexDatabaseRanking":24},{"id":69,"createTime":24,"updateTime":24,"relativeEntities":1777,"label":1778,"description":1779,"key":76,"publicationTags":1780,"standard":24},[],{"EN":72,"VI":72},{"EN":74,"VI":75},[78,79],[82],{"issue":1783,"pages":1785,"volume":1787},{"VOID":1784},"5",{"VOID":1786},"3044-3060",{"VOID":1788},"29",502,{"total":1789,"publishYear":24,"statisticByYear":1791},{"2022":1792,"2023":1793,"2024":1794},29,163,300,[],[1797,1801,1805,1809,1813,1817,1821,1825,1829,1833,1837,1841,1845,1849,1853,1857,1861,1865,1869,1873,1877,1881,1885,1888,1892,1896,1900,1904,1908,1912,1916,1920,1924,1927,1931,1935,1939,1943,1947,1951,1955,1959,1963,1967,1971,1975,1979,1983,1987,1991,1995,1999,2003,2007,2011,2015,2019,2023,2027,2031,2035,2039,2043,2047,2051,2054,2058,2062,2066,2070,2074,2078,2082,2086,2090,2094,2098,2102,2106,2110,2114,2118,2121,2125,2129,2133,2137,2141,2145,2149,2153,2157,2161,2164,2168,2172,2176,2180,2184,2188,2192,2196,2200,2204,2208,2212,2216,2220,2224,2228,2232,2236,2240,2244,2248,2252,2256,2260,2264,2268,2272,2276,2280,2284,2288,2292,2296,2300,2304,2308,2312,2316,2320,2324,2328,2332,2336,2340,2344,2348,2352,2356,2360,2364,2368,2372,2376],{"id":24,"text":1798,"url":24,"identifiers":1799},"Smith, 2021, Clinical cancer advances 2021: ASCO’s Report on progress against cancer, J. Clin. Oncol., 39, 1165, 10.1200\u002FJCO.20.03420",{"doi":1800},"10.1200\u002FJCO.20.03420",{"id":24,"text":1802,"url":24,"identifiers":1803},"Monkman, 2021, Understanding the tumor microenvironment for effective immunotherapy, Med. Res. Rev., 41, 1474, 10.1002\u002Fmed.21765",{"doi":1804},"10.1002\u002Fmed.21765",{"id":24,"text":1806,"url":24,"identifiers":1807},"Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., and Deshmukh, R.R. (2020). Immunotherapies and Combination Strategies for Immuno-Oncology. Int. J. Mol. Sci., 21.",{"doi":1808},"10.3390\u002Fijms21145009",{"id":24,"text":1810,"url":24,"identifiers":1811},"Seidel, 2018, Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations, Front. Oncol., 8, 86, 10.3389\u002Ffonc.2018.00086",{"doi":1812},"10.3389\u002Ffonc.2018.00086",{"id":24,"text":1814,"url":24,"identifiers":1815},"Liebl, 2019, Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?, J. Eur. Acad. Dermatol. Venereol., 33, 52, 10.1111\u002Fjdv.15992",{"doi":1816},"10.1111\u002Fjdv.15992",{"id":24,"text":1818,"url":24,"identifiers":1819},"Paucek, 2019, The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy, Trends Immunol., 40, 292, 10.1016\u002Fj.it.2019.02.002",{"doi":1820},"10.1016\u002Fj.it.2019.02.002",{"id":24,"text":1822,"url":24,"identifiers":1823},"Rizzo, 2022, PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: How can they assist drug clinical trials?, Expert Opin. Investig. Drugs, 31, 415, 10.1080\u002F13543784.2021.1972969",{"doi":1824},"10.1080\u002F13543784.2021.1972969",{"id":24,"text":1826,"url":24,"identifiers":1827},"Rizzo, A., Mollica, V., Santoni, M., Ricci, A.D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., and Massari, F. (2021). Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. Eur. Urol. Focus.",{"doi":1828},"10.1016\u002Fj.euf.2021.03.001",{"id":24,"text":1830,"url":24,"identifiers":1831},"Rad, 2021, The Pandora’s box of novel technologies that may revolutionize lung cancer, Lung Cancer, 159, 34, 10.1016\u002Fj.lungcan.2021.06.022",{"doi":1832},"10.1016\u002Fj.lungcan.2021.06.022",{"id":24,"text":1834,"url":24,"identifiers":1835},"Kulasinghe, 2022, Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC), Front. Oncol., 11, 798296, 10.3389\u002Ffonc.2021.798296",{"doi":1836},"10.3389\u002Ffonc.2021.798296",{"id":24,"text":1838,"url":24,"identifiers":1839},"Kulasinghe, 2021, Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients, Front. Oncol., 10, 3118, 10.3389\u002Ffonc.2020.607349",{"doi":1840},"10.3389\u002Ffonc.2020.607349",{"id":24,"text":1842,"url":24,"identifiers":1843},"Monkman, J., Taheri, T., Ebrahimi Warkiani, M., O’leary, C., Ladwa, R., Richard, D., O’Byrne, K., and Kulasinghe, A. (2020). High-plex and high-throughput digital spatial profiling of Non-Small-Cell Lung Cancer (NSCLC). Cancers, 12.",{"doi":1844},"10.1101\u002F2020.07.22.20160325",{"id":24,"text":1846,"url":24,"identifiers":1847},"Robert, 2020, A decade of immune-checkpoint inhibitors in cancer therapy, Nat. Commun., 11, 3801, 10.1038\u002Fs41467-020-17670-y",{"doi":1848},"10.1038\u002Fs41467-020-17670-y",{"id":24,"text":1850,"url":24,"identifiers":1851},"Ledford, 2011, Melanoma drug wins US approval, Nature, 471, 561, 10.1038\u002F471561a",{"doi":1852},"10.1038\u002F471561a",{"id":24,"text":1854,"url":24,"identifiers":1855},"Johnson, 2022, Immune-checkpoint inhibitors: Long-term implications of toxicity, Nat. Rev. Clin. Oncol., 19, 254, 10.1038\u002Fs41571-022-00600-w",{"doi":1856},"10.1038\u002Fs41571-022-00600-w",{"id":24,"text":1858,"url":24,"identifiers":1859},"Cai, 2021, Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases, Front. Genet., 12, 2352, 10.3389\u002Ffgene.2021.785153",{"doi":1860},"10.3389\u002Ffgene.2021.785153",{"id":24,"text":1862,"url":24,"identifiers":1863},"Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038\u002Fnrc3239",{"doi":1864},"10.1038\u002Fnrc3239",{"id":24,"text":1866,"url":24,"identifiers":1867},"Chrétien, S., Zerdes, I., Bergh, J., Matikas, A., and Foukakis, T. (2019). Beyond PD-1\u002FPD-L1 inhibition: What the future holds for breast cancer immunotherapy. Cancers, 11.",{"doi":1868},"10.3390\u002Fcancers11050628",{"id":24,"text":1870,"url":24,"identifiers":1871},"Rolfo, 2017, Immunotherapy in NSCLC: A Promising and Revolutionary Weapon, Immunotherapy, 995, 97, 10.1007\u002F978-3-319-53156-4_5",{"doi":1872},"10.1007\u002F978-3-319-53156-4_5",{"id":24,"text":1874,"url":24,"identifiers":1875},"Wu, 2021, Therapeutic Effects of Pembrolizumab Combined with Paclitaxel and Cisplatin Chemotherapy on Advanced Non-Squamous Non-Small Cell Lung Cancer and Influencing Factors, Indian J. Pharm. Sci., 83, 120, 10.36468\u002Fpharmaceutical-sciences.757",{"doi":1876},"10.36468\u002Fpharmaceutical-sciences.757",{"id":24,"text":1878,"url":24,"identifiers":1879},"Li, 2019, Current clinical progress of PD-1\u002FPD-L1 immunotherapy and potential combination treatment in non–small cell lung cancer, Integr. Cancer Ther., 18, 1534735419890020, 10.1177\u002F1534735419890020",{"doi":1880},"10.1177\u002F1534735419890020",{"id":24,"text":1882,"url":24,"identifiers":1883},"Migden, 2018, PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma, N. Engl. J. Med., 379, 341, 10.1056\u002FNEJMoa1805131",{"doi":1884},"10.1056\u002FNEJMoa1805131",{"id":24,"text":1886,"url":24,"identifiers":1887},"Mansh, 2011, Ipilimumab and cancer immunotherapy: A new hope for advanced stage melanoma, Yale J. Biol. Med., 84, 381",{},{"id":24,"text":1889,"url":24,"identifiers":1890},"Shirley, 2018, Avelumab: A Review in Metastatic Merkel Cell Carcinoma, Target. Oncol., 13, 409, 10.1007\u002Fs11523-018-0571-4",{"doi":1891},"10.1007\u002Fs11523-018-0571-4",{"id":24,"text":1893,"url":24,"identifiers":1894},"Spira, 2020, Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial, Ann. Oncol., 31, 798, 10.1016\u002Fj.annonc.2020.03.287",{"doi":1895},"10.1016\u002Fj.annonc.2020.03.287",{"id":24,"text":1897,"url":24,"identifiers":1898},"Rocco, 2022, Chemotherapy plus single\u002Fdouble immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: Where do we stand and where are we going?, Expert Rev. Anticancer Ther., 22, 183, 10.1080\u002F14737140.2022.2026772",{"doi":1899},"10.1080\u002F14737140.2022.2026772",{"id":24,"text":1901,"url":24,"identifiers":1902},"Mazieres, 2020, Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer, J. Clin. Oncol., 38, 271, 10.1200\u002FJCO.19.01348",{"doi":1903},"10.1200\u002FJCO.19.01348",{"id":24,"text":1905,"url":24,"identifiers":1906},"Reck, 2019, Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Rev. Respir. Med., 14, 125, 10.1080\u002F17476348.2020.1701439",{"doi":1907},"10.1080\u002F17476348.2020.1701439",{"id":24,"text":1909,"url":24,"identifiers":1910},"Mohsenzadegan, 2021, The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine Metab. Immune Disord.—Drug Targets, 21, 2131, 10.2174\u002F1871530321666210310142141",{"doi":1911},"10.2174\u002F1871530321666210310142141",{"id":24,"text":1913,"url":24,"identifiers":1914},"Qin, 2019, Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4, Mol. Cancer, 18, 155, 10.1186\u002Fs12943-019-1091-2",{"doi":1915},"10.1186\u002Fs12943-019-1091-2",{"id":24,"text":1917,"url":24,"identifiers":1918},"Saleh, R., Toor, S.M., Khalaf, S., and Elkord, E. (2019). Breast Cancer Cells and PD-1\u002FPD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells. Vaccines, 7.",{"doi":1919},"10.3390\u002Fvaccines7040149",{"id":24,"text":1921,"url":24,"identifiers":1922},"Riella, 2012, Role of the PD-1 Pathway in the Immune Response, Am. J. Transplant., 12, 2575, 10.1111\u002Fj.1600-6143.2012.04224.x",{"doi":1923},"10.1111\u002Fj.1600-6143.2012.04224.x",{"id":24,"text":1925,"url":24,"identifiers":1926},"Han, 2020, PD-1\u002FPD-L1 pathway: Current researches in cancer, Am. J. Cancer Res., 10, 727",{},{"id":24,"text":1928,"url":24,"identifiers":1929},"Huang, 2021, Comparative Efficacy and Safety of PD-1\u002FPD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis, J. Cancer, 12, 1133, 10.7150\u002Fjca.49325",{"doi":1930},"10.7150\u002Fjca.49325",{"id":24,"text":1932,"url":24,"identifiers":1933},"Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial, Lancet Oncol., 16, 257, 10.1016\u002FS1470-2045(15)70054-9",{"doi":1934},"10.1016\u002FS1470-2045(15)70054-9",{"id":24,"text":1936,"url":24,"identifiers":1937},"Kazandjian, 2016, FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy, Oncologist, 21, 634, 10.1634\u002Ftheoncologist.2015-0507",{"doi":1938},"10.1634\u002Ftheoncologist.2015-0507",{"id":24,"text":1940,"url":24,"identifiers":1941},"Brahmer, 2010, Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200\u002FJCO.2009.26.7609",{"doi":1942},"10.1200\u002FJCO.2009.26.7609",{"id":24,"text":1944,"url":24,"identifiers":1945},"Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., and Antonuzzo, L. (2021). Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 13.",{"doi":1946},"10.3390\u002Fcancers13040860",{"id":24,"text":1948,"url":24,"identifiers":1949},"Giudice, 2021, Pembrolizumab for advanced cervical cancer: Safety and efficacy, Expert Rev. Anticancer. Ther., 21, 221, 10.1080\u002F14737140.2021.1850279",{"doi":1950},"10.1080\u002F14737140.2021.1850279",{"id":24,"text":1952,"url":24,"identifiers":1953},"Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126\u002Fscience.aan6733",{"doi":1954},"10.1126\u002Fscience.aan6733",{"id":24,"text":1956,"url":24,"identifiers":1957},"Groisberg, 2017, Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials, J. Immunother. Cancer, 5, 100, 10.1186\u002Fs40425-017-0301-y",{"doi":1958},"10.1186\u002Fs40425-017-0301-y",{"id":24,"text":1960,"url":24,"identifiers":1961},"Inokuchi, 2019, Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma, Cancer Manag. Res., 11, 4519, 10.2147\u002FCMAR.S167708",{"doi":1962},"10.2147\u002FCMAR.S167708",{"id":24,"text":1964,"url":24,"identifiers":1965},"Vuky, 2020, Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer, J. Clin. Oncol., 38, 2658, 10.1200\u002FJCO.19.01213",{"doi":1966},"10.1200\u002FJCO.19.01213",{"id":24,"text":1968,"url":24,"identifiers":1969},"Burtness, 2019, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study, Lancet, 394, 1915, 10.1016\u002FS0140-6736(19)32591-7",{"doi":1970},"10.1016\u002FS0140-6736(19)32591-7",{"id":24,"text":1972,"url":24,"identifiers":1973},"Chen, 2021, Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer, J. Chin. Med Assoc., 84, 361, 10.1097\u002FJCMA.0000000000000497",{"doi":1974},"10.1097\u002FJCMA.0000000000000497",{"id":24,"text":1976,"url":24,"identifiers":1977},"Argenziano, 2022, Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: An expert opinion, Ther. Adv. Med. Oncol., 14, 17588359211066272, 10.1177\u002F17588359211066272",{"doi":1978},"10.1177\u002F17588359211066272",{"id":24,"text":1980,"url":24,"identifiers":1981},"Stratigos, 2020, European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention, Eur. J. Cancer, 128, 60, 10.1016\u002Fj.ejca.2020.01.007",{"doi":1982},"10.1016\u002Fj.ejca.2020.01.007",{"id":24,"text":1984,"url":24,"identifiers":1985},"Villani, 2021, Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma, Expert Opin. Drug Saf., 21, 21, 10.1080\u002F14740338.2022.1993819",{"doi":1986},"10.1080\u002F14740338.2022.1993819",{"id":24,"text":1988,"url":24,"identifiers":1989},"Migden, 2020, Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial, Lancet Oncol., 21, 294, 10.1016\u002FS1470-2045(19)30728-4",{"doi":1990},"10.1016\u002FS1470-2045(19)30728-4",{"id":24,"text":1992,"url":24,"identifiers":1993},"Keeping, 2021, Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma, Futur. Oncol., 17, 611, 10.2217\u002Ffon-2020-0823",{"doi":1994},"10.2217\u002Ffon-2020-0823",{"id":24,"text":1996,"url":24,"identifiers":1997},"Sezer, 2021, Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial, Lancet, 397, 592, 10.1016\u002FS0140-6736(21)00228-2",{"doi":1998},"10.1016\u002FS0140-6736(21)00228-2",{"id":24,"text":2000,"url":24,"identifiers":2001},"Battin, 2019, Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\u002FPD-L1 signaling, Sci. Rep., 9, 11472, 10.1038\u002Fs41598-019-47910-1",{"doi":2002},"10.1038\u002Fs41598-019-47910-1",{"id":24,"text":2004,"url":24,"identifiers":2005},"Doroshow, 2021, PD-L1 as a biomarker of response to immune-checkpoint inhibitors, Nat. Rev. Clin. Oncol., 18, 345, 10.1038\u002Fs41571-021-00473-5",{"doi":2006},"10.1038\u002Fs41571-021-00473-5",{"id":24,"text":2008,"url":24,"identifiers":2009},"Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038\u002Fnature14011",{"doi":2010},"10.1038\u002Fnature14011",{"id":24,"text":2012,"url":24,"identifiers":2013},"Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat. Med., 5, 1365, 10.1038\u002F70932",{"doi":2014},"10.1038\u002F70932",{"id":24,"text":2016,"url":24,"identifiers":2017},"Shah, 2017, Product review on the Anti-PD-L1 antibody atezolizumab, Hum. Vaccines Immunother., 14, 269, 10.1080\u002F21645515.2017.1403694",{"doi":2018},"10.1080\u002F21645515.2017.1403694",{"id":24,"text":2020,"url":24,"identifiers":2021},"Herbst, 2020, Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC, N. Engl. J. Med., 383, 1328, 10.1056\u002FNEJMoa1917346",{"doi":2022},"10.1056\u002FNEJMoa1917346",{"id":24,"text":2024,"url":24,"identifiers":2025},"Kaplan, 2022, Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases, Curr. Oncol. Rep., 24, 343, 10.1007\u002Fs11912-022-01206-2",{"doi":2026},"10.1007\u002Fs11912-022-01206-2",{"id":24,"text":2028,"url":24,"identifiers":2029},"Inman, 2016, Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer, Clin. Cancer Res., 23, 1886, 10.1158\u002F1078-0432.CCR-16-1417",{"doi":2030},"10.1158\u002F1078-0432.CCR-16-1417",{"id":24,"text":2032,"url":24,"identifiers":2033},"Weinstock, 2017, Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer, Clin. Cancer Res., 23, 4534, 10.1158\u002F1078-0432.CCR-17-0540",{"doi":2034},"10.1158\u002F1078-0432.CCR-17-0540",{"id":24,"text":2036,"url":24,"identifiers":2037},"Park, 2018, 136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR), J. Thorac. Oncol., 13, S79, 10.1016\u002FS1556-0864(18)30410-6",{"doi":2038},"10.1016\u002FS1556-0864(18)30410-6",{"id":24,"text":2040,"url":24,"identifiers":2041},"Schmid, 2018, Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, N. Engl. J. Med., 379, 2108, 10.1056\u002FNEJMoa1809615",{"doi":2042},"10.1056\u002FNEJMoa1809615",{"id":24,"text":2044,"url":24,"identifiers":2045},"Collins, 2019, Product review: Avelumab, an anti-PD-L1 antibody, Hum. Vaccines Immunother., 15, 891, 10.1080\u002F21645515.2018.1551671",{"doi":2046},"10.1080\u002F21645515.2018.1551671",{"id":24,"text":2048,"url":24,"identifiers":2049},"Gaiser, 2018, PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma, Expert Rev. Clin. Pharmacol., 11, 345, 10.1080\u002F17512433.2018.1445966",{"doi":2050},"10.1080\u002F17512433.2018.1445966",{"id":24,"text":2052,"url":24,"identifiers":2053},"Bhatia, 2019, Avelumab in patients with previously treated metastatic Merkel cell carcinoma: Long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial, J. Immunother. Cancer, 8, e000674",{},{"id":24,"text":2055,"url":24,"identifiers":2056},"Choueiri, 2018, Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial, Lancet Oncol., 19, 451, 10.1016\u002FS1470-2045(18)30107-4",{"doi":2057},"10.1016\u002FS1470-2045(18)30107-4",{"id":24,"text":2059,"url":24,"identifiers":2060},"Larkin, 2016, Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma, J. Clin. Oncol., 34, TPS4580, 10.1200\u002FJCO.2016.34.15_suppl.TPS4580",{"doi":2061},"10.1200\u002FJCO.2016.34.15_suppl.TPS4580",{"id":24,"text":2063,"url":24,"identifiers":2064},"Simeone, 2019, Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting, Futur. Oncol., 15, 3491, 10.2217\u002Ffon-2019-0348",{"doi":2065},"10.2217\u002Ffon-2019-0348",{"id":24,"text":2067,"url":24,"identifiers":2068},"Stewart, 2015, Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody, Cancer Immunol. Res., 3, 1052, 10.1158\u002F2326-6066.CIR-14-0191",{"doi":2069},"10.1158\u002F2326-6066.CIR-14-0191",{"id":24,"text":2071,"url":24,"identifiers":2072},"Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J. Clin. Oncol., 34, 3119, 10.1200\u002FJCO.2016.67.9761",{"doi":2073},"10.1200\u002FJCO.2016.67.9761",{"id":24,"text":2075,"url":24,"identifiers":2076},"Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N. Engl. J. Med., 379, 2342, 10.1056\u002FNEJMoa1809697",{"doi":2077},"10.1056\u002FNEJMoa1809697",{"id":24,"text":2079,"url":24,"identifiers":2080},"Rizvi, 2020, Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: The MYSTIC phase 3 randomized clinical trial, JAMA Oncol., 6, 661, 10.1001\u002Fjamaoncol.2020.0237",{"doi":2081},"10.1001\u002Fjamaoncol.2020.0237",{"id":24,"text":2083,"url":24,"identifiers":2084},"Brunet, 1987, A new member of the immunoglobulin superfamily—CTLA-4, Nature, 328, 267, 10.1038\u002F328267a0",{"doi":2085},"10.1038\u002F328267a0",{"id":24,"text":2087,"url":24,"identifiers":2088},"Rudd, 2009, CD28 and CTLA-4 coreceptor expression and signal transduction, Immunol. Rev., 229, 12, 10.1111\u002Fj.1600-065X.2009.00770.x",{"doi":2089},"10.1111\u002Fj.1600-065X.2009.00770.x",{"id":24,"text":2091,"url":24,"identifiers":2092},"Linsley, 1992, Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule, Science, 257, 792, 10.1126\u002Fscience.1496399",{"doi":2093},"10.1126\u002Fscience.1496399",{"id":24,"text":2095,"url":24,"identifiers":2096},"Egen, 2002, Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength, Immunity, 16, 23, 10.1016\u002FS1074-7613(01)00259-X",{"doi":2097},"10.1016\u002FS1074-7613(01)00259-X",{"id":24,"text":2099,"url":24,"identifiers":2100},"Leach, 1996, Enhancement of Antitumor Immunity by CTLA-4 Blockade, Science, 271, 1734, 10.1126\u002Fscience.271.5256.1734",{"doi":2101},"10.1126\u002Fscience.271.5256.1734",{"id":24,"text":2103,"url":24,"identifiers":2104},"Qureshi, 2011, Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4, Science, 332, 600, 10.1126\u002Fscience.1202947",{"doi":2105},"10.1126\u002Fscience.1202947",{"id":24,"text":2107,"url":24,"identifiers":2108},"Gavin, 2007, Foxp3-dependent programme of regulatory T-cell differentiation, Nature, 445, 771, 10.1038\u002Fnature05543",{"doi":2109},"10.1038\u002Fnature05543",{"id":24,"text":2111,"url":24,"identifiers":2112},"Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies, J. Exp. Med., 206, 1717, 10.1084\u002Fjem.20082492",{"doi":2113},"10.1084\u002Fjem.20082492",{"id":24,"text":2115,"url":24,"identifiers":2116},"Callahan, 2013, At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy, J. Leukoc. Biol., 94, 41, 10.1189\u002Fjlb.1212631",{"doi":2117},"10.1189\u002Fjlb.1212631",{"id":24,"text":2119,"url":24,"identifiers":2120},"Mullard, 2015, FDA approves first immunotherapy combo, Nat. Rev. Drug Discov., 14, 739",{},{"id":24,"text":2122,"url":24,"identifiers":2123},"Lisi, 2021, Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment, Pharmacol. Res., 175, 105997, 10.1016\u002Fj.phrs.2021.105997",{"doi":2124},"10.1016\u002Fj.phrs.2021.105997",{"id":24,"text":2126,"url":24,"identifiers":2127},"Fecher, 2013, Ipilimumab and Its Toxicities: A Multidisciplinary Approach, Oncologist, 18, 733, 10.1634\u002Ftheoncologist.2012-0483",{"doi":2128},"10.1634\u002Ftheoncologist.2012-0483",{"id":24,"text":2130,"url":24,"identifiers":2131},"Bajorin, 2021, Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma, N. Engl. J. Med., 384, 2102, 10.1056\u002FNEJMoa2034442",{"doi":2132},"10.1056\u002FNEJMoa2034442",{"id":24,"text":2134,"url":24,"identifiers":2135},"Reck, 2019, Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater, J. Clin. Oncol., 37, 537, 10.1200\u002FJCO.18.00149",{"doi":2136},"10.1200\u002FJCO.18.00149",{"id":24,"text":2138,"url":24,"identifiers":2139},"Fenizia, 2018, Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy, Transl. Lung Cancer Res., 7, 668, 10.21037\u002Ftlcr.2018.09.23",{"doi":2140},"10.21037\u002Ftlcr.2018.09.23",{"id":24,"text":2142,"url":24,"identifiers":2143},"Falvo, 2020, Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer, Cancer Res., 81, 685, 10.1158\u002F0008-5472.CAN-20-1818",{"doi":2144},"10.1158\u002F0008-5472.CAN-20-1818",{"id":24,"text":2146,"url":24,"identifiers":2147},"Parra, 2017, Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth, Br. J. Cancer, 116, 324, 10.1038\u002Fbjc.2016.429",{"doi":2148},"10.1038\u002Fbjc.2016.429",{"id":24,"text":2150,"url":24,"identifiers":2151},"Babiker, 2021, Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Oncologist, 26, e1508, 10.1002\u002Fonco.13810",{"doi":2152},"10.1002\u002Fonco.13810",{"id":24,"text":2154,"url":24,"identifiers":2155},"Zheng, 2018, Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model, J. Immunother., 41, 361, 10.1097\u002FCJI.0000000000000242",{"doi":2156},"10.1097\u002FCJI.0000000000000242",{"id":24,"text":2158,"url":24,"identifiers":2159},"Hurwitz, 1999, Combination immunotherapy of B16 melanoma using anti–cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and granulocyte\u002Fmacrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, J. Exp. Med., 190, 355, 10.1084\u002Fjem.190.3.355",{"doi":2160},"10.1084\u002Fjem.190.3.355",{"id":24,"text":2162,"url":24,"identifiers":2163},"Hurwitz, 2000, Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade, Cancer Res., 60, 2444",{},{"id":24,"text":2165,"url":24,"identifiers":2166},"Soares, 2015, PD-1\u002FPD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors, J. Immunother., 38, 1, 10.1097\u002FCJI.0000000000000062",{"doi":2167},"10.1097\u002FCJI.0000000000000062",{"id":24,"text":2169,"url":24,"identifiers":2170},"Derer, 2015, Immune-modulating properties of ionizing radiation: Rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors, Cancer Immunol. Immunother., 65, 779, 10.1007\u002Fs00262-015-1771-8",{"doi":2171},"10.1007\u002Fs00262-015-1771-8",{"id":24,"text":2173,"url":24,"identifiers":2174},"Stessin, 2020, Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice, J. Neuro-Oncol., 147, 547, 10.1007\u002Fs11060-020-03459-y",{"doi":2175},"10.1007\u002Fs11060-020-03459-y",{"id":24,"text":2177,"url":24,"identifiers":2178},"Hendriks, 2018, Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy, Transl. Lung Cancer Res., 7, 647, 10.21037\u002Ftlcr.2018.09.22",{"doi":2179},"10.21037\u002Ftlcr.2018.09.22",{"id":24,"text":2181,"url":24,"identifiers":2182},"Li, 2020, Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects, Mol. Cancer, 19, 116, 10.1186\u002Fs12943-020-01234-1",{"doi":2183},"10.1186\u002Fs12943-020-01234-1",{"id":24,"text":2185,"url":24,"identifiers":2186},"Behrens, 2017, The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1\u002FPD-1: A future perspective for a combined gastric cancer therapy?, Oncoimmunology, 6, e1293215, 10.1080\u002F2162402X.2017.1293215",{"doi":2187},"10.1080\u002F2162402X.2017.1293215",{"id":24,"text":2189,"url":24,"identifiers":2190},"Chen, 2012, Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clin. Cancer Res., 18, 6580, 10.1158\u002F1078-0432.CCR-12-1362",{"doi":2191},"10.1158\u002F1078-0432.CCR-12-1362",{"id":24,"text":2193,"url":24,"identifiers":2194},"Ran, 2017, Inhibitors of the PD-1\u002FPD-L1 axis for the treatment of head and neck cancer: Current status and future perspectives, Drug Des. Dev. Ther., 11, 2007, 10.2147\u002FDDDT.S140687",{"doi":2195},"10.2147\u002FDDDT.S140687",{"id":24,"text":2197,"url":24,"identifiers":2198},"Rad, 2020, The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies, Clin. Transl. Immunol., 9, e1215, 10.1002\u002Fcti2.1215",{"doi":2199},"10.1002\u002Fcti2.1215",{"id":24,"text":2201,"url":24,"identifiers":2202},"Brahmer, 2020, Immune-related adverse events of checkpoint inhibitors, Nat. Rev. Dis. Primers, 6, 38, 10.1038\u002Fs41572-020-0160-6",{"doi":2203},"10.1038\u002Fs41572-020-0160-6",{"id":24,"text":2205,"url":24,"identifiers":2206},"Bellmunt, 2017, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med., 376, 1015, 10.1056\u002FNEJMoa1613683",{"doi":2207},"10.1056\u002FNEJMoa1613683",{"id":24,"text":2209,"url":24,"identifiers":2210},"Schmid, 2020, Pembrolizumab for Early Triple-Negative Breast Cancer, N. Engl. J. Med., 382, 810, 10.1056\u002FNEJMoa1910549",{"doi":2211},"10.1056\u002FNEJMoa1910549",{"id":24,"text":2213,"url":24,"identifiers":2214},"Yau, 2020, Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial, JAMA Oncol., 6, e204564, 10.1001\u002Fjamaoncol.2020.4564",{"doi":2215},"10.1001\u002Fjamaoncol.2020.4564",{"id":24,"text":2217,"url":24,"identifiers":2218},"Sha, 2020, Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors, Cancer Discov., 10, 1808, 10.1158\u002F2159-8290.CD-20-0522",{"doi":2219},"10.1158\u002F2159-8290.CD-20-0522",{"id":24,"text":2221,"url":24,"identifiers":2222},"Xiao, J., Li, W., Huang, Y., Huang, M., Li, S., Zhai, X., Zhao, J., Gao, C., Xie, W., and Qin, H. (2021). A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer, 21.",{"doi":2223},"10.1186\u002Fs12885-021-07942-1",{"id":24,"text":2225,"url":24,"identifiers":2226},"Berland, 2019, Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors, J. Thorac. Dis., 11, S71, 10.21037\u002Fjtd.2018.11.102",{"doi":2227},"10.21037\u002Fjtd.2018.11.102",{"id":24,"text":2229,"url":24,"identifiers":2230},"Shao, 2020, Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors, JAMA Netw. Open, 3, e2025109, 10.1001\u002Fjamanetworkopen.2020.25109",{"doi":2231},"10.1001\u002Fjamanetworkopen.2020.25109",{"id":24,"text":2233,"url":24,"identifiers":2234},"Marabelle, 2019, Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158, Ann. Oncol., 30, v477, 10.1093\u002Fannonc\u002Fmdz253.018",{"doi":2235},"10.1093\u002Fannonc\u002Fmdz253.018",{"id":24,"text":2237,"url":24,"identifiers":2238},"Yarchoan, 2017, Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N. Engl. J. Med., 377, 2500, 10.1056\u002FNEJMc1713444",{"doi":2239},"10.1056\u002FNEJMc1713444",{"id":24,"text":2241,"url":24,"identifiers":2242},"Li, 2020, Microsatellite instability: A review of what the oncologist should know, Cancer Cell Int., 20, 16, 10.1186\u002Fs12935-019-1091-8",{"doi":2243},"10.1186\u002Fs12935-019-1091-8",{"id":24,"text":2245,"url":24,"identifiers":2246},"Randrian, V., Evrard, C., and Tougeron, D. (2021). Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers, 13.",{"doi":2247},"10.3390\u002Fcancers13123063",{"id":24,"text":2249,"url":24,"identifiers":2250},"Haraldsdottir, 2014, Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations, Gastroenterology, 147, 1308, 10.1053\u002Fj.gastro.2014.08.041",{"doi":2251},"10.1053\u002Fj.gastro.2014.08.041",{"id":24,"text":2253,"url":24,"identifiers":2254},"Luchini, 2019, ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\u002FPD-L1 expression and tumour mutational burden: A systematic review-based approach, Ann. Oncol., 30, 1232, 10.1093\u002Fannonc\u002Fmdz116",{"doi":2255},"10.1093\u002Fannonc\u002Fmdz116",{"id":24,"text":2257,"url":24,"identifiers":2258},"Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016\u002FS1470-2045(17)30422-9",{"doi":2259},"10.1016\u002FS1470-2045(17)30422-9",{"id":24,"text":2261,"url":24,"identifiers":2262},"Dekaboruah, 2020, Human microbiome: An academic update on human body site specific surveillance and its possible role, Arch. Microbiol., 202, 2147, 10.1007\u002Fs00203-020-01931-x",{"doi":2263},"10.1007\u002Fs00203-020-01931-x",{"id":24,"text":2265,"url":24,"identifiers":2266},"Yi, 2018, The role of gut microbiota in immune checkpoint inhibitor therapy, Hepatobiliary Surg. Nutr., 7, 481, 10.21037\u002Fhbsn.2018.11.12",{"doi":2267},"10.21037\u002Fhbsn.2018.11.12",{"id":24,"text":2269,"url":24,"identifiers":2270},"Xu, 2020, Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway, Front. Microbiol., 11, 814, 10.3389\u002Ffmicb.2020.00814",{"doi":2271},"10.3389\u002Ffmicb.2020.00814",{"id":24,"text":2273,"url":24,"identifiers":2274},"Liu, 2021, Gut microbiota-mediated immunomodulation in tumor, J. Exp. Clin. Cancer Res., 40, 221, 10.1186\u002Fs13046-021-01983-x",{"doi":2275},"10.1186\u002Fs13046-021-01983-x",{"id":24,"text":2277,"url":24,"identifiers":2278},"Matson, 2018, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients, Science, 359, 104, 10.1126\u002Fscience.aao3290",{"doi":2279},"10.1126\u002Fscience.aao3290",{"id":24,"text":2281,"url":24,"identifiers":2282},"Zheng, 2019, Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma, J. Immunother. Cancer, 7, 193, 10.1186\u002Fs40425-019-0650-9",{"doi":2283},"10.1186\u002Fs40425-019-0650-9",{"id":24,"text":2285,"url":24,"identifiers":2286},"Vordermark, 2016, Hypoxia as a Biomarker and for Personalized Radiation Oncology, Mol. Radio-Oncol., 198, 123, 10.1007\u002F978-3-662-49651-0_6",{"doi":2287},"10.1007\u002F978-3-662-49651-0_6",{"id":24,"text":2289,"url":24,"identifiers":2290},"Waller, J., Onderdonk, B., Flood, A., Swartz, H., Shah, J., Shah, A., Aydogan, B., Halpern, H., and Hasan, Y. (2020). The clinical utility of imaging methods used to measure hypoxia in cervical cancer. Br. J. Radiol., 93.",{"doi":2291},"10.1259\u002Fbjr.20190640",{"id":24,"text":2293,"url":24,"identifiers":2294},"Hu, 2021, The regulation of immune checkpoints by the hypoxic tumor microenvironment, PeerJ, 9, e11306, 10.7717\u002Fpeerj.11306",{"doi":2295},"10.7717\u002Fpeerj.11306",{"id":24,"text":2297,"url":24,"identifiers":2298},"Jankovic, 2006, Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix, Cytom. Part B Clin. Cytom. J. Int. Soc. Anal. Cytol., 70, 45, 10.1002\u002Fcyto.b.20086",{"doi":2299},"10.1002\u002Fcyto.b.20086",{"id":24,"text":2301,"url":24,"identifiers":2302},"Zandberg, 2021, Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck, J. Immunother. Cancer, 9, e002088, 10.1136\u002Fjitc-2020-002088",{"doi":2303},"10.1136\u002Fjitc-2020-002088",{"id":24,"text":2305,"url":24,"identifiers":2306},"Lee, 2021, Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\u002FKEYNOTE-146): A phase 1b\u002F2 study, Lancet Oncol., 22, 946, 10.1016\u002FS1470-2045(21)00241-2",{"doi":2307},"10.1016\u002FS1470-2045(21)00241-2",{"id":24,"text":2309,"url":24,"identifiers":2310},"Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016\u002Fj.cell.2010.01.025",{"doi":2311},"10.1016\u002Fj.cell.2010.01.025",{"id":24,"text":2313,"url":24,"identifiers":2314},"Jorgovanovic, 2020, Roles of IFN-γ in tumor progression and regression: A review, Biomark. Res., 8, 49, 10.1186\u002Fs40364-020-00228-x",{"doi":2315},"10.1186\u002Fs40364-020-00228-x",{"id":24,"text":2317,"url":24,"identifiers":2318},"Castro, 2018, Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion, Front. Immunol., 9, 847, 10.3389\u002Ffimmu.2018.00847",{"doi":2319},"10.3389\u002Ffimmu.2018.00847",{"id":24,"text":2321,"url":24,"identifiers":2322},"Gocher, 2021, Interferon-γ: Teammate or opponent in the tumour microenvironment?, Nat. Rev. Immunol., 22, 158, 10.1038\u002Fs41577-021-00566-3",{"doi":2323},"10.1038\u002Fs41577-021-00566-3",{"id":24,"text":2325,"url":24,"identifiers":2326},"Zaidi, 2019, The interferon-gamma paradox in cancer, J. Interferon Cytokine Res., 39, 30, 10.1089\u002Fjir.2018.0087",{"doi":2327},"10.1089\u002Fjir.2018.0087",{"id":24,"text":2329,"url":24,"identifiers":2330},"Ivashkiv, 2018, IFNγ: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy, Nat. Rev. Immunol., 18, 545, 10.1038\u002Fs41577-018-0029-z",{"doi":2331},"10.1038\u002Fs41577-018-0029-z",{"id":24,"text":2333,"url":24,"identifiers":2334},"Mo, 2017, Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4, Cancer Res., 78, 436, 10.1158\u002F0008-5472.CAN-17-1615",{"doi":2335},"10.1158\u002F0008-5472.CAN-17-1615",{"id":24,"text":2337,"url":24,"identifiers":2338},"Dholaria, 2018, Next generation of immune checkpoint therapy in cancer: New developments and challenges, J. Hematol. Oncol., 11, 39, 10.1186\u002Fs13045-018-0582-8",{"doi":2339},"10.1186\u002Fs13045-018-0582-8",{"id":24,"text":2341,"url":24,"identifiers":2342},"Frantz, 2010, The extracellular matrix at a glance, J. Cell Sci., 123, 4195, 10.1242\u002Fjcs.023820",{"doi":2343},"10.1242\u002Fjcs.023820",{"id":24,"text":2345,"url":24,"identifiers":2346},"Gordon-Weeks, A., and Yuzhalin, A.E. (2020). Cancer Extracellular Matrix Proteins Regulate Tumour Immunity. Cancers, 12.",{"doi":2347},"10.3390\u002Fcancers12113331",{"id":24,"text":2349,"url":24,"identifiers":2350},"Bulle, 2020, Beyond just a tight fortress: Contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer, Signal Transduct. Target. Ther., 5, 249, 10.1038\u002Fs41392-020-00341-1",{"doi":2351},"10.1038\u002Fs41392-020-00341-1",{"id":24,"text":2353,"url":24,"identifiers":2354},"Huang, 2021, Extracellular matrix and its therapeutic potential for cancer treatment, Signal Transduct. Target. Ther., 6, 153, 10.1038\u002Fs41392-021-00544-0",{"doi":2355},"10.1038\u002Fs41392-021-00544-0",{"id":24,"text":2357,"url":24,"identifiers":2358},"Brassart, 2020, Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression, Front. Oncol., 10, 397, 10.3389\u002Ffonc.2020.00397",{"doi":2359},"10.3389\u002Ffonc.2020.00397",{"id":24,"text":2361,"url":24,"identifiers":2362},"Vaquero, 2021, Author response: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment, Elife, 10, e58688, 10.7554\u002FeLife.58688",{"doi":2363},"10.7554\u002FeLife.58688",{"id":24,"text":2365,"url":24,"identifiers":2366},"Triebel, 1990, LAG-3, a novel lymphocyte activation gene closely related to CD4, J. Exp. Med., 171, 1393, 10.1084\u002Fjem.171.5.1393",{"doi":2367},"10.1084\u002Fjem.171.5.1393",{"id":24,"text":2369,"url":24,"identifiers":2370},"Hodi, 2010, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N. Engl. J. Med., 363, 711, 10.1056\u002FNEJMoa1003466",{"doi":2371},"10.1056\u002FNEJMoa1003466",{"id":24,"text":2373,"url":24,"identifiers":2374},"Helbling, 2017, Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, Clin. Oncol., 29, 218, 10.1016\u002Fj.clon.2016.11.007",{"doi":2375},"10.1016\u002Fj.clon.2016.11.007",{"id":24,"text":2377,"url":24,"identifiers":2378},"Naidoo, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol., 26, 2375, 10.1093\u002Fannonc\u002Fmdv383",{"doi":2379},"10.1093\u002Fannonc\u002Fmdv383"]